Breaking News

Thursday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Hot Stocks	Philips incorporates Biodesix's Nodify Lung blood-based testing into its system » 09:07 06/30/22 06/30 09:07 06/30/22 09:07 PHG Philips $21.33 / +0.035 (+0.16%) , BDSX Biodesix $1.36 / -0.02 (-1.45%) Royal Philips (PHG)… Royal Philips (PHG) announced it has teamed up with Biodesix (BDSX) to incorporate the results of Biodesix's Nodify Lung blood-based lung nodule risk assessment testing into Philips Lung Cancer Orchestrator lung cancer patient management system. The incorporation of proteomics data - along with the radiologic and patient history data currently used to determine treatment decisions - can help create diagnostic efficiency for cancer care centers in the management of a growing number of lung nodule cases, via the contextual launch of Biodesix Nodify Lung application within Lung Cancer Orchestrator. "By incorporating Biodesix's Nodify Lung testing, we take another step in leveraging integrated diagnostics from imaging, genomics, and now proteomic results from a simple blood draw to address key moments in the lung cancer patient journey, support care team decision-making, and help health systems learn from their practice patterns in a dashboard view," said Louis Culot, General Manager Oncology Informatics and Genomics at Philips. "We expect the inclusion of Biodesix's ground-breaking technology in Philips Lung Cancer Orchestrator to help drive more confident decisions for the care team, and ultimately benefit patients." ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options PHG BDSX PHG Philips $21.33 / +0.035 (+0.16%) 06/13/22 Philips to repurchase up to 3.2M shares 06/13/22 Philips announces three-year clinical research results from TOBA II BTK trial 06/13/22 Garmin announces dismissal of Philips patent lawsuit by U.S. District Court 05/09/22 Philips receives FDA 510(k) clearance for new MR 7700 3.0T MR system BDSX Biodesix $1.36 / -0.02 (-1.45%) 06/07/22 Biodesix obtains Medicare coverage for Nodify CDT lung nodule test 06/03/22 Biodesix announces research agreement with top U.S. cancer center 04/11/22 Biodesix director Strobeck buys $1M in company shares 03/29/22 Biodesix announces publication of data from GeneStrat NGS test studies PHG BDSX PHG Philips $21.33 / +0.035 (+0.16%) 06/29/22 Deutsche Bank Philips price target lowered to EUR 25 from EUR 30 at Deutsche Bank 06/16/22 UBS Philips downgraded to Sell from Neutral at UBS 05/25/22 JPMorgan Philips price target lowered to EUR 21.30 from EUR 26.50 at JPMorgan 05/25/22 JPMorgan Philips downgraded to Underweight from Neutral at JPMorgan BDSX Biodesix $1.36 / -0.02 (-1.45%) 06/13/22 Canaccord Biodesix's Medicare coverage a meaningful milestone, says Canaccord 05/12/22 Canaccord Biodesix price target lowered to $7 from $10 at Canaccord 04/20/22 Cowen Biodesix initiated with an Outperform at Cowen 04/18/22 BTIG Biodesix price target lowered to $10 from $17 at BTIG PHG BDSX PHG Philips $21.33 / +0.035 (+0.16%) 04/25/22 Philips reports Q1 adjusted EPS EUR 0.28 vs. EUR 0.15 last year 01/24/22 Philips reports Q4 adjusted EPS EUR 0.57 vs. EUR 0.83 last year 01/12/22 Philips sees FY21 group revenue EUR 17.2B 01/12/22 Philips sees Q4 group revenue EUR 4.9B BDSX Biodesix $1.36 / -0.02 (-1.45%) 05/11/22 Biodesix still sees 2022 revenue $37.5M-$39.5M, consensus $38.41M 05/11/22 Biodesix reports Q1 EPS (50c), consensus (40c) 03/14/22 Biodesix sees FY22 revenue $37.5M-$39.5M, consensus $35.5M 03/14/22 Biodesix reports Q4 EPS (49c), consensus (49c) PHG BDSX PHG Philips $21.33 / +0.035 (+0.16%) 04/25/22 What You Missed On Wall Street On Monday 04/25/22 What You Missed On Wall Street This Morning 04/25/22 Fly Intel: Pre-market Movers 01/24/22 Wall Street in Fives - Must Read Lists for Monday BDSX Biodesix $1.36 / -0.02 (-1.45%) 04/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/12/22 Fly Intel: Pre-market Movers 04/11/22 Fly Intel: After-Hours Movers BDSX BDSX Biodesix $1.36 / -0.02 (-1.45%) 04/12/22 Unusually active option classes on open April 12th

Over a week ago
Conference/Events	Jefferies to hold a conference » 04:55 06/22/22 06/22 04:55 06/22/22 04:55 ABST Absolute Software $8.16 / +0.25 (+3.16%) , BANR Banner Corp. $55.97 / +1.93 (+3.57%) , CDW CDW $159.89 / +3.39 (+2.17%) , DGII Digi International $23.26 / +0.55 (+2.42%) , SKIN Beauty Health $11.78 / +0.52 (+4.62%) , XPOF Xponential Fitness $12.85 / -0.02 (-0.16%) , ATRI Atrion $624.30 / -7.32 (-1.16%) , CCMP CMC Materials $174.42 / +1.68 (+0.97%) , DEN Denbury $67.13 / +3.42 (+5.37%) , LNDC Landec $10.11 / +0.36 (+3.69%) , SKLZ Skillz $1.39 / +0.045 (+3.35%) , TRNS Transcat $59.18 / +0.24 (+0.41%) , TCX Tucows $40.93 / -0.96 (-2.29%) , TBI TrueBlue $16.83 / +0.585 (+3.60%) , SCHL Scholastic $35.53 / +0.04 (+0.11%) , SBEV Splash Beverage $2.06 / +0.24 (+13.19%) , EBET EBET $2.62 / -0.125 (-4.55%) , BEST Best Inc. $1.22 / +0.01 (+0.83%) , BDSX Biodesix $1.33 / -0.12 (-8.28%) , CHKP Check Point $120.11 / +0.71 (+0.59%) , CHEK Check-Cap / + , EAR Eargo $1.03 / -0.02 (-1.90%) , LVLU Lulu's Fashion Lounge $12.27 / -0.4 (-3.16%) , LMND Lemonade $17.70 / +0.215 (+1.23%) Consumer Conference to be… Consumer Conference to be held in Nantucket, MA on June 20-22. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options XPOF TRNS TCX TBI SKLZ SKIN SCHL SBEV LNDC LMND EBET EAR DEN CHKP CHEK CDW CCMP BEST BDSX BANR ABST XPOF Xponential Fitness $12.85 / -0.02 (-0.16%) 05/10/22 Xponential Fitness in franchise pact in Mexico for three brands 04/21/22 Xponential Fitness enters collaboration with Lululemon, MIRROR 04/05/22 Xponential Fitness falls -8.5% 04/05/22 Xponential Fitness falls -8.2% TRNS Transcat $59.18 / +0.24 (+0.41%) 05/23/22 Transcat 'well positioned for profitable growth' in FY23, beyond 02/01/22 Transcat sees Q4 Service revenue growth in high teens 01/03/22 Transcat buys privately-held Tangent Labs for $9M TCX Tucows $40.93 / -0.96 (-2.29%) 02/10/22 Tucows approves $40M stock buyback program 01/07/22 Ting Internet to be initial anchor tenant of Colorado Spring Utilities' network TBI TrueBlue $16.83 / +0.585 (+3.60%) 06/15/22 TrueBlue's Cooper: Beharelle's resignation in the best interests of the company 06/15/22 TrueBlue names Chairman Steven Cooper as CEO 06/15/22 TrueBlue announces resignation of CEO Patrick Beharelle, effective June 14 06/15/22 TrueBlue investigation found Beharelle's behaviors violated code of conduct SKLZ Skillz $1.39 / +0.045 (+3.35%) 03/23/22 Skillz announces multiyear partnership with UFC SKIN Beauty Health $11.78 / +0.52 (+4.62%) 05/11/22 Beauty Health announces partnership with Jennifer Lopez's JLo Beauty 05/09/22 Beauty Health appoints Amy Juaristi as head of corporate affairs 01/20/22 Beauty Health announces Andrew Stanleick as President and CEO SCHL Scholastic $35.53 / +0.04 (+0.11%) 03/21/22 Scholastic appoints Cristina Juvier as CPO SBEV Splash Beverage $2.06 / +0.24 (+13.19%) 05/24/22 Splash Beverage signs distribution agreement with Buck Distributing 05/04/22 Splash Beverage's TapouT to be offered in Bashas' Family of Stores 04/27/22 Splash Beverage extends distribution into upper midwest 04/19/22 Splash Beverage appoints Ron Wall as CFO LNDC Landec $10.11 / +0.36 (+3.69%) 06/02/22 Landec completes $3.2M Curation Foods sale LMND Lemonade $17.70 / +0.215 (+1.23%) 05/10/22 Lemonade trading resumes 05/10/22 Lemonade trading halted, volatility trading pause 05/09/22 Lemonade up 4% after Q1 reports 02/01/22 Metromile shareholders approve merger agreement with Lemonade EBET EBET $2.62 / -0.125 (-4.55%) 05/19/22 EBET announces agreement with Captain Up 05/04/22 Esports Technologies changes name to EBET 04/19/22 Esports Technologies announces agreement with Incentive Games 02/23/22 Esports Technologies files quantum computing patent EAR Eargo $1.03 / -0.02 (-1.90%) 05/31/22 Nasdaq confirms continued listing of Eargo stock 05/13/22 Eargo receives Nasdaq non-compliance letter 04/29/22 Eargo sees Q1 gross systems shipped 5,770 04/29/22 Eargo enters civil settlement agreement with U.S. DOJ DEN Denbury $67.13 / +3.42 (+5.37%) 05/18/22 Denbury, Nutrien enter agreement for transportation and storage of CO2 05/05/22 Denbury backs previous 2022 production guidance 05/05/22 Denbury announces $250M share repurchase program 03/16/22 Denbury announces new agreements in Louisiana's industrial corridor CHKP Check Point $120.11 / +0.71 (+0.59%) 05/17/22 Check Point to partner with Provision-ISR 04/27/22 Check Point CFO 'hopes' supply chain constraints are temporary 04/05/22 Pax8, Check Point enter agreement for cloud-based email security solutions 03/02/22 Check Point launches unified go-to-market organization CHEK Check-Cap / + 05/11/22 Check-Cap initiates trial of C-Scan at Mayo Clinic in Rochester Minnesota 02/07/22 Check-Cap announces FDA approval of amended IDE application for C-Scan study 12/23/21 Check-Cap receives Nasdaq minimum bid price notification CDW CDW $159.89 / +3.39 (+2.17%) 06/10/22 CDW announces addition of two new strategy, marketing executives CCMP CMC Materials $174.42 / +1.68 (+0.97%) 05/02/22 TricorBraun appoints Scott Beamer as CFO 04/08/22 Entegris COO Todd Edlund to retire from the company 03/03/22 CMC Materials shareholders approve merger with Entegris 02/15/22 CMC Materials reports 'favorable' conclusion in patent dispute with DuPont BEST Best Inc. $1.22 / +0.01 (+0.83%) 06/09/22 Best Inc. regains NYSE compliance 05/10/22 Best Inc. announces plans to implement ADS ratio change 04/21/22 Li Auto, KE Holdings among new additions to SEC HFCAA provisional list 01/18/22 Best Inc. receives noncompliance notification from NYSE BDSX Biodesix $1.33 / -0.12 (-8.28%) 06/07/22 Biodesix obtains Medicare coverage for Nodify CDT lung nodule test 06/03/22 Biodesix announces research agreement with top U.S. cancer center 04/11/22 Biodesix director Strobeck buys $1M in company shares 03/29/22 Biodesix announces publication of data from GeneStrat NGS test studies BANR Banner Corp. $55.97 / +1.93 (+3.57%) 05/19/22 Banner Corp. says shareholders approved all proposals at annual meeting 03/04/22 Banner Corp. announces Copeland, Walsh appointed to board of directors 12/22/21 Banner announces 1.7M share repurchase agreement, 5% of its common stock ABST Absolute Software $8.16 / +0.25 (+3.16%) 06/06/22 Absolute Software announces new partnerships with ISVs 'leveraging' APaaS 03/07/22 Absolute Software CFO Steven Gatoff departs, Ron Fior named interim CFO ABST BANR CDW DGII SKIN XPOF ATRI CCMP DEN LNDC SKLZ TRNS TCX TBI SCHL SBEV EBET BEST BDSX CHKP CHEK EAR LVLU LMND ABST Absolute Software $8.16 / +0.25 (+3.16%) 05/11/22 BMO Capital Absolute Software price target lowered to C$12 from C$14 at BMO Capital 05/11/22 Canaccord Absolute Software price target lowered to $17 from $22 at Canaccord 02/09/22 BMO Capital Absolute Software price target lowered to C$14 from C$18.50 at BMO Capital 02/09/22 TD Securities TD Securities upgrades Absolute Software to Buy after 'another' beat and raise BANR Banner Corp. $55.97 / +1.93 (+3.57%) 06/17/22 Stephens Stephens upgrades Banner to Overweight as Street mismodels rate sensitivity 06/17/22 Stephens Banner Corp. upgraded to Overweight from Equal Weight at Stephens 01/24/22 Raymond James Banner Corp. price target raised to $72 from $68 at Raymond James 09/07/21 DA Davidson Banner Corp. downgraded to Neutral from Buy at DA Davidson CDW CDW $159.89 / +3.39 (+2.17%) 05/05/22 Evercore ISI CDW removed from 'TAP Outperform' list at Evercore ISI 04/18/22 Evercore ISI CDW added to 'TAP Outperform' list at Evercore ISI 04/14/22 Stifel CDW upgraded to Buy at Stifel following recent pullback 04/14/22 Stifel CDW upgraded to Buy from Hold at Stifel DGII Digi International $23.26 / +0.55 (+2.42%) 06/01/22 Stephens Digi International initiated with an Overweight at Stephens 02/03/22 Canaccord Digi International price target raised to $30 from $28 at Canaccord 11/11/21 Roth Capital Digi International price target raised to $33 from $28 at Roth Capital 11/11/21 Canaccord Digi International price target raised to $28 from $25 at Canaccord SKIN Beauty Health $11.78 / +0.52 (+4.62%) 05/11/22 Canaccord Beauty Health price target lowered to $22 from $27 at Canaccord 05/11/22 DA Davidson Beauty Health price target lowered to $24 from $35 at DA Davidson 05/11/22 Piper Sandler Beauty Health price target lowered to $24 from $26 at Piper Sandler 04/28/22 Piper Sandler Beauty Health price target lowered to $26 from $31 at Piper Sandler XPOF Xponential Fitness $12.85 / -0.02 (-0.16%) 06/13/22 Jefferies Jefferies names five top picks in lifestyle and growth platforms 03/14/22 Evercore ISI Evercore ISI starts Xponential Fitness at Outperform with $34 price target 03/14/22 Evercore ISI Xponential Fitness initiated with an Outperform at Evercore ISI 03/14/22 Baird Xponential Fitness price target raised to $28 from $26 at Baird ATRI Atrion $624.30 / -7.32 (-1.16%) CCMP CMC Materials $174.42 / +1.68 (+0.97%) 04/07/22 CL King CMC Materials downgraded to Neutral from Buy at CL King 04/07/22 CL King CMC Materials downgraded to Neutral from Buy at CL King 02/04/22 Mizuho CMC Materials downgraded to Neutral from Buy at Mizuho 12/17/21 Citi CMC Materials upgraded to Neutral after buyout at Citi DEN Denbury $67.13 / +3.42 (+5.37%) 05/24/22 Citi California Resources, Denbury may be takeout targets, says Citi 05/10/22 Citi Denbury initiated with a Buy at Citi 05/05/22 Stifel Denbury price target raised to $129 from $126 at Stifel 04/26/22 KeyBanc KeyBanc says Axios report positive for Plug Power, other fuel cell names LNDC Landec $10.11 / +0.36 (+3.69%) 04/06/22 Barrington Landec downgraded to Market Perform from Outperform at Barrington 09/30/21 Barrington Landec price target lowered to $12 from $14 at Barrington SKLZ Skillz $1.39 / +0.045 (+3.35%) 05/23/22 Citi Skillz downgraded to Neutral from Buy at Citi 03/01/22 Citi Skillz price target lowered to $5 from $9 at Citi 02/24/22 Stifel Skillz price target lowered to $3.50 from $16 at Stifel 02/24/22 Wedbush Skillz price target lowered to $7.50 from $25 at Wedbush TRNS Transcat $59.18 / +0.24 (+0.41%) 06/02/22 H.C. Wainwright Transcat price target lowered to $85 from $105 at H.C. Wainwright 05/26/22 Roth Capital Transcat price target lowered to $80 from $97 at Roth Capital 05/25/22 Craig-Hallum Transcat price target lowered to $81 from $94 at Craig-Hallum 02/03/22 Craig-Hallum Pullback in Transcat shares creates buying opportunity, says Craig-Hallum TCX Tucows $40.93 / -0.96 (-2.29%) TBI TrueBlue $16.83 / +0.585 (+3.60%) 05/26/22 BMO Capital TrueBlue downgraded to Market Perform from Outperform at BMO Capital 04/11/22 Sidoti TrueBlue reinstated with a Buy at Sidoti 10/26/21 Baird TrueBlue price target raised to $35 from $31 at Baird SCHL Scholastic $35.53 / +0.04 (+0.11%) SBEV Splash Beverage $2.06 / +0.24 (+13.19%) 04/25/22 EF Hutton Splash Beverage initiated with a Buy at EF Hutton EBET EBET $2.62 / -0.125 (-4.55%) 02/07/22 Needham Needham starts Esports Technologies at Buy on esports betting opportunity 02/07/22 Needham Esports Technologies initiated with a Buy at Needham BEST Best Inc. $1.22 / +0.01 (+0.83%) BDSX Biodesix $1.33 / -0.12 (-8.28%) 06/13/22 Canaccord Biodesix's Medicare coverage a meaningful milestone, says Canaccord 05/12/22 Canaccord Biodesix price target lowered to $7 from $10 at Canaccord 04/20/22 Cowen Biodesix initiated with an Outperform at Cowen 04/18/22 BTIG Biodesix price target lowered to $10 from $17 at BTIG CHKP Check Point $120.11 / +0.71 (+0.59%) 05/23/22 Jefferies Check Point price target lowered to $130 from $145 at Jefferies 04/28/22 Barclays Check Point price target lowered to $145 from $160 at Barclays 04/28/22 Credit Suisse Check Point price target raised to $115 from $105 at Credit Suisse 04/28/22 Wells Fargo Check Point price target lowered to $130 from $144 at Wells Fargo CHEK Check-Cap / + 02/07/22 Check-Cap upgraded to Buy from Neutral at Dawson James EAR Eargo $1.03 / -0.02 (-1.90%) 09/23/21 Fly Intel: Top five analyst downgrades 09/23/21 William Blair William Blair downgrades Eargo on 'multiple unknowns' from criminal probe 09/23/21 Wells Fargo Wells Fargo cuts Eargo to Equal Weight, slashes price target $10 from $52 09/23/21 William Blair Eargo downgraded to Market Perform from Outperform at William Blair LVLU Lulu's Fashion Lounge $12.27 / -0.4 (-3.16%) 06/10/22 BofA Lulu's Fashion Lounge downgraded to Neutral from Buy at BofA 01/14/22 Jefferies Jefferies still believes in strength of Lulu's model after management meetings 12/06/21 Cowen Cowen starts Lulu's Fashion Lounge with Outperform, affordable luxury brand 12/06/21 Baird Baird starts Lulu's Fashion Lounge with Outperform, sees attractive value LMND Lemonade $17.70 / +0.215 (+1.23%) 05/11/22 Oppenheimer Lemonade price target lowered to $30 from $45 at Oppenheimer 05/11/22 JMP Securities Lemonade price target lowered to $40 from $95 at JMP Securities 02/25/22 Barclays Lemonade price target lowered to $22 from $43 at Barclays 02/25/22 Oppenheimer Lemonade price target lowered to $45 from $85 at Oppenheimer XPOF TRNS TBI SKLZ SKIN SBEV LVLU LNDC LMND DGII DEN CHKP CHEK CDW CCMP BDSX BANR ABST XPOF Xponential Fitness $12.85 / -0.02 (-0.16%) 05/12/22 Xponential Fitness backs FY22 revenue $201M-$211M, consensus $209.85M 05/12/22 Xponential Fitness reports Q1 adjusted EPS (19c), consensus 12c 03/03/22 Xponential Fitness sees FY22 revenue $201M-$211M, consensus $199.54M 03/03/22 Xponential Fitness reports Q4 adjusted EPS (21c), consensus (14c) TRNS Transcat $59.18 / +0.24 (+0.41%) 05/23/22 Transcat sees FY22 adjusted EPS $2.03, consensus $1.72 02/01/22 Transcat reports Q3 EPS 21c, consensus 25c TBI TrueBlue $16.83 / +0.585 (+3.60%) 04/25/22 TrueBlue reports Q1 adjusted EPS 44c, consensus 35c 02/02/22 TrueBlue reports Q4 adjusted EPS 69c, consensus 43c SKLZ Skillz $1.39 / +0.045 (+3.35%) 05/04/22 Skillz sees FY22 revenue view $400M, consensus $399.24M 05/04/22 Skillz reports Q1 EPS (37c), consensus (18c) 02/23/22 Skillz sees FY22 revenue $400M, consensus $548.8M 02/23/22 Skillz reports Q4 EPS (25c), consensus (15c) SKIN Beauty Health $11.78 / +0.52 (+4.62%) 05/10/22 Beauty Health raises FY22 revenue view to $330M-$340M from $320M-$330M 05/10/22 Beauty Health reports Q1 EPS (13c), consensus (1c) 02/22/22 Beauty Health sees FY22 revenue $320M-$330M, consensus $314M 02/22/22 Beauty Health reports Q4 EPS (12c), consensus (2c) SBEV Splash Beverage $2.06 / +0.24 (+13.19%) 05/16/22 Splash Beverage reports Q1 revenue $4.1M vs $2.2M last year LVLU Lulu's Fashion Lounge $12.27 / -0.4 (-3.16%) 05/17/22 Lulu's Fashion Lounge sees FY22 revenue $490M-$500M, consensus $486.92M 05/17/22 Lulu's Fashion Lounge reports Q1 EPS 5c, consensus 5c 04/01/22 Lulu's Fashion Lounge sees FY22 revenue of $480M-$490M, consensus $472.06M 03/31/22 Lulu's Fashion Lounge reports Q4 EPS (3c), consensus (7c) LNDC Landec $10.11 / +0.36 (+3.69%) 04/05/22 Landec sees FY22 revenue $179M-$185M , consensus $182,01M 04/05/22 Landec reports Q3 EPS (8c), consensus 0c 01/05/22 Landec reports Q2 EPS ($1.30), consensus (7c) LMND Lemonade $17.70 / +0.215 (+1.23%) 05/09/22 Lemonade sees FY22 revenue $205M-$208M, consensus $216.49M 05/09/22 Lemonade sees Q2 revenue $46M-48M, consensus $51.83M 05/09/22 Lemonade reports Q1 EPS ($1.21), consensus ($1.43) 05/09/22 Notable companies reporting after market close DGII Digi International $23.26 / +0.55 (+2.42%) 05/04/22 Digi International sees Q3 EPS 37c-40c, consensus 37c 05/04/22 Digi International reports Q2 EPS 41c, consensus 32c 02/02/22 Digi International sees Q2 adjusted EPS 33c-37c, consensus 32c 02/02/22 Digi International reports Q1 adjusted EPS 36c, consensus 29c DEN Denbury $67.13 / +3.42 (+5.37%) 05/05/22 Denbury reports Q1 adjusted EPS $1.69, consensus $1.53 02/24/22 Denbury reports Q4 adjusted EPS 76c, consensus 70c CHKP Check Point $120.11 / +0.71 (+0.59%) 04/27/22 Check Point backs FY22 EPS view $6.90-$7.50, consensus $7.25 04/27/22 Check Point sees Q2 adjusted EPS $1.55-$1.65, consensus $1.65 04/27/22 Check Point reports Q1 EPS $1.57, consensus $1.54 02/03/22 Check Point sees FY22 EPS $6.90-$7.50, consensus $7.34 CHEK Check-Cap / + 04/07/22 Check-Cap reports Q4 EPS (8c), consensus (3c) CDW CDW $159.89 / +3.39 (+2.17%) 05/04/22 CDW reports Q1 EPS $2.20, consensus $2.01 02/09/22 CDW reports Q4 EPS $2.08, consensus $1.93 CCMP CMC Materials $174.42 / +1.68 (+0.97%) 05/04/22 CMC Materials sees Q3 revenue flat from Q2, consensus $317.4M 05/04/22 CMC Materials reports Q2 EPS $1.94, consensus $1.81 02/02/22 CMC Materials reports Q1 adjusted EPS $2.06, consensus $1.77 BDSX Biodesix $1.33 / -0.12 (-8.28%) 05/11/22 Biodesix still sees 2022 revenue $37.5M-$39.5M, consensus $38.41M 05/11/22 Biodesix reports Q1 EPS (50c), consensus (40c) 03/14/22 Biodesix sees FY22 revenue $37.5M-$39.5M, consensus $35.5M 03/14/22 Biodesix reports Q4 EPS (49c), consensus (49c) BANR Banner Corp. $55.97 / +1.93 (+3.57%) 04/20/22 Banner Corp. reports Q1 EPS $1.27, consensus $1.09 ABST Absolute Software $8.16 / +0.25 (+3.16%) 05/10/22 Absolute Software ups FY22 revenue view to $209.5M-$210.5M, consensus $207.35M 05/10/22 Absolute Software reports Q3 EPS (13c), consensus (10c) 02/08/22 Absolute Software raises FY22 revenue view to $206M-$208M, consensus $206.04M 02/08/22 Absolute Software reports Q2 EPS (10c), consensus (8c) 07 Apr 15 Feb 11 Nov 23 Jul LMND CHKP LMND Lemonade $17.70 / +0.215 (+1.23%) 02/14/22 Socially conscious sock maker Bombas exploring IPO, Bloomberg says CHKP Check Point $120.11 / +0.71 (+0.59%) 03/14/22 Israeli government sites crash in cyberattack, Haaretz reports XPOF TRNS TBI SKLZ SKIN SBEV LVLU LNDC EBET DEN CHKP CDW BDSX BANR XPOF Xponential Fitness $12.85 / -0.02 (-0.16%) 04/05/22 What You Missed On Wall Street This Morning 04/05/22 Fly Intel: Pre-market Movers 04/04/22 Fly Intel: After-Hours Movers TRNS Transcat $59.18 / +0.24 (+0.41%) 02/01/22 Fly Intel: After-Hours Movers TBI TrueBlue $16.83 / +0.585 (+3.60%) 05/26/22 What You Missed On Wall Street On Thursday 05/26/22 What You Missed On Wall Street This Morning SKLZ Skillz $1.39 / +0.045 (+3.35%) 02/23/22 Fly Intel: After-Hours Movers SKIN Beauty Health $11.78 / +0.52 (+4.62%) 06/17/22 Sell these stocks now, proven algorithm says 05/27/22 Sell these stocks now, proven algorithm says 05/13/22 Proven algorithm says sell these stocks now 02/23/22 What You Missed On Wall Street On Wednesday SBEV Splash Beverage $2.06 / +0.24 (+13.19%) 03/24/22 Meet Splash Beverage: Fly exclusive interview with CEO Robert Nistico 02/14/22 Fly Intel: After-Hours Movers LVLU Lulu's Fashion Lounge $12.27 / -0.4 (-3.16%) 05/17/22 Fly Intel: After-Hours Movers 04/01/22 What You Missed On Wall Street On Friday 04/01/22 What You Missed On Wall Street This Morning 04/01/22 Fly Intel: Pre-market Movers LNDC Landec $10.11 / +0.36 (+3.69%) 01/18/22 Fly Insider: Landec, AMC Entertainment among week's notable insider trades 01/05/22 Fly Intel: After-Hours Movers EBET EBET $2.62 / -0.125 (-4.55%) 02/07/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations DEN Denbury $67.13 / +3.42 (+5.37%) 05/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations CHKP Check Point $120.11 / +0.71 (+0.59%) 04/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/21/22 What You Missed On Wall Street On Monday 03/21/22 What You Missed On Wall Street This Morning 03/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations CDW CDW $159.89 / +3.39 (+2.17%) 04/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BDSX Biodesix $1.33 / -0.12 (-8.28%) 04/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/12/22 Fly Intel: Pre-market Movers 04/11/22 Fly Intel: After-Hours Movers BANR Banner Corp. $55.97 / +1.93 (+3.57%) 06/17/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/22/22 Energy, Power, & Renewables Conference 2022 06/28/22 Beauty Health Company (The) SKLZ SKIN SBEV LNDC LMND EBET EAR BEST BDSX BANR SKLZ Skillz $1.39 / +0.045 (+3.35%) 05/04/22 Skillz options imply 19.9% move in share price post-earnings 02/23/22 Skillz options imply 20.8% move in share price post-earnings 01/11/22 Skillz call volume above normal and directionally bullish SKIN Beauty Health $11.78 / +0.52 (+4.62%) 02/15/22 Beauth Health Company call buyer realizes 50% same-day gains 01/28/22 Beauth Health Company put volume heavy and directionally bearish SBEV Splash Beverage $2.06 / +0.24 (+13.19%) 02/23/22 Largest borrow rate increases among liquid names 01/21/22 One new option listing on January 21st LNDC Landec $10.11 / +0.36 (+3.69%) 01/05/22 Landec options imply 3.9% move in share price post-earnings LMND Lemonade $17.70 / +0.215 (+1.23%) 04/25/22 Lemonade call volume above normal and directionally bullish 04/05/22 Lemonade put volume heavy and directionally bearish 03/30/22 Lemonade put volume heavy and directionally bearish EBET EBET $2.62 / -0.125 (-4.55%) 06/14/22 Largest borrow rate increases among liquid names 02/04/22 Seven new option listings and one option delisting on February 4th EAR Eargo $1.03 / -0.02 (-1.90%) 03/07/22 Eargo options imply 12.6% move in share price post-earnings 02/10/22 Eargo options imply 10.7% move in share price post-earnings 02/03/22 Eargo options imply 9.5% move in share price post-earnings 01/27/22 Eargo options imply 14.5% move in share price post-earnings BEST Best Inc. $1.22 / +0.01 (+0.83%) 03/08/22 BEST Inc options imply 58.0% move in share price post-earnings BDSX Biodesix $1.33 / -0.12 (-8.28%) 04/12/22 Unusually active option classes on open April 12th BANR Banner Corp. $55.97 / +1.93 (+3.57%) 01/20/22 Banner Corp. options imply 5.9% move in share price post-earnings
Conference/Events	Jefferies to hold a conference » 00:03 06/22/22 06/22 00:03 06/22/22 00:03 ABST Absolute Software $8.16 / +0.25 (+3.16%) , BANR Banner Corp. $55.97 / +1.93 (+3.57%) , CDW CDW $159.89 / +3.39 (+2.17%) , DGII Digi International $23.26 / +0.55 (+2.42%) , SKIN Beauty Health $11.78 / +0.52 (+4.62%) , XPOF Xponential Fitness $12.85 / -0.02 (-0.16%) , ATRI Atrion $624.30 / -7.32 (-1.16%) , CCMP CMC Materials $174.42 / +1.68 (+0.97%) , DEN Denbury $67.13 / +3.42 (+5.37%) , LNDC Landec $10.11 / +0.36 (+3.69%) , SKLZ Skillz $1.39 / +0.045 (+3.35%) , TRNS Transcat $59.18 / +0.24 (+0.41%) , TCX Tucows $40.93 / -0.96 (-2.29%) , TBI TrueBlue $16.83 / +0.585 (+3.60%) , SCHL Scholastic $35.53 / +0.04 (+0.11%) , SBEV Splash Beverage $2.06 / +0.24 (+13.19%) , EBET EBET $2.62 / -0.125 (-4.55%) , BEST Best Inc. $1.22 / +0.01 (+0.83%) , BDSX Biodesix $1.33 / -0.12 (-8.28%) , CHKP Check Point $120.11 / +0.71 (+0.59%) , CHEK Check-Cap / + , EAR Eargo $1.03 / -0.02 (-1.90%) , LVLU Lulu's Fashion Lounge $12.27 / -0.4 (-3.16%) , LMND Lemonade $17.70 / +0.215 (+1.23%) Consumer Conference to be… Consumer Conference to be held in Nantucket, MA on June 20-22. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options XPOF TRNS TCX TBI SKLZ SKIN SCHL SBEV LNDC LMND EBET EAR DEN CHKP CHEK CDW CCMP BEST BDSX BANR ABST XPOF Xponential Fitness $12.85 / -0.02 (-0.16%) 05/10/22 Xponential Fitness in franchise pact in Mexico for three brands 04/21/22 Xponential Fitness enters collaboration with Lululemon, MIRROR 04/05/22 Xponential Fitness falls -8.5% 04/05/22 Xponential Fitness falls -8.2% TRNS Transcat $59.18 / +0.24 (+0.41%) 05/23/22 Transcat 'well positioned for profitable growth' in FY23, beyond 02/01/22 Transcat sees Q4 Service revenue growth in high teens 01/03/22 Transcat buys privately-held Tangent Labs for $9M TCX Tucows $40.93 / -0.96 (-2.29%) 02/10/22 Tucows approves $40M stock buyback program 01/07/22 Ting Internet to be initial anchor tenant of Colorado Spring Utilities' network TBI TrueBlue $16.83 / +0.585 (+3.60%) 06/15/22 TrueBlue's Cooper: Beharelle's resignation in the best interests of the company 06/15/22 TrueBlue names Chairman Steven Cooper as CEO 06/15/22 TrueBlue announces resignation of CEO Patrick Beharelle, effective June 14 06/15/22 TrueBlue investigation found Beharelle's behaviors violated code of conduct SKLZ Skillz $1.39 / +0.045 (+3.35%) 03/23/22 Skillz announces multiyear partnership with UFC SKIN Beauty Health $11.78 / +0.52 (+4.62%) 05/11/22 Beauty Health announces partnership with Jennifer Lopez's JLo Beauty 05/09/22 Beauty Health appoints Amy Juaristi as head of corporate affairs 01/20/22 Beauty Health announces Andrew Stanleick as President and CEO SCHL Scholastic $35.53 / +0.04 (+0.11%) 03/21/22 Scholastic appoints Cristina Juvier as CPO SBEV Splash Beverage $2.06 / +0.24 (+13.19%) 05/24/22 Splash Beverage signs distribution agreement with Buck Distributing 05/04/22 Splash Beverage's TapouT to be offered in Bashas' Family of Stores 04/27/22 Splash Beverage extends distribution into upper midwest 04/19/22 Splash Beverage appoints Ron Wall as CFO LNDC Landec $10.11 / +0.36 (+3.69%) 06/02/22 Landec completes $3.2M Curation Foods sale LMND Lemonade $17.70 / +0.215 (+1.23%) 05/10/22 Lemonade trading resumes 05/10/22 Lemonade trading halted, volatility trading pause 05/09/22 Lemonade up 4% after Q1 reports 02/01/22 Metromile shareholders approve merger agreement with Lemonade EBET EBET $2.62 / -0.125 (-4.55%) 05/19/22 EBET announces agreement with Captain Up 05/04/22 Esports Technologies changes name to EBET 04/19/22 Esports Technologies announces agreement with Incentive Games 02/23/22 Esports Technologies files quantum computing patent EAR Eargo $1.03 / -0.02 (-1.90%) 05/31/22 Nasdaq confirms continued listing of Eargo stock 05/13/22 Eargo receives Nasdaq non-compliance letter 04/29/22 Eargo sees Q1 gross systems shipped 5,770 04/29/22 Eargo enters civil settlement agreement with U.S. DOJ DEN Denbury $67.13 / +3.42 (+5.37%) 05/18/22 Denbury, Nutrien enter agreement for transportation and storage of CO2 05/05/22 Denbury backs previous 2022 production guidance 05/05/22 Denbury announces $250M share repurchase program 03/16/22 Denbury announces new agreements in Louisiana's industrial corridor CHKP Check Point $120.11 / +0.71 (+0.59%) 05/17/22 Check Point to partner with Provision-ISR 04/27/22 Check Point CFO 'hopes' supply chain constraints are temporary 04/05/22 Pax8, Check Point enter agreement for cloud-based email security solutions 03/02/22 Check Point launches unified go-to-market organization CHEK Check-Cap / + 05/11/22 Check-Cap initiates trial of C-Scan at Mayo Clinic in Rochester Minnesota 02/07/22 Check-Cap announces FDA approval of amended IDE application for C-Scan study 12/23/21 Check-Cap receives Nasdaq minimum bid price notification CDW CDW $159.89 / +3.39 (+2.17%) 06/10/22 CDW announces addition of two new strategy, marketing executives CCMP CMC Materials $174.42 / +1.68 (+0.97%) 05/02/22 TricorBraun appoints Scott Beamer as CFO 04/08/22 Entegris COO Todd Edlund to retire from the company 03/03/22 CMC Materials shareholders approve merger with Entegris 02/15/22 CMC Materials reports 'favorable' conclusion in patent dispute with DuPont BEST Best Inc. $1.22 / +0.01 (+0.83%) 06/09/22 Best Inc. regains NYSE compliance 05/10/22 Best Inc. announces plans to implement ADS ratio change 04/21/22 Li Auto, KE Holdings among new additions to SEC HFCAA provisional list 01/18/22 Best Inc. receives noncompliance notification from NYSE BDSX Biodesix $1.33 / -0.12 (-8.28%) 06/07/22 Biodesix obtains Medicare coverage for Nodify CDT lung nodule test 06/03/22 Biodesix announces research agreement with top U.S. cancer center 04/11/22 Biodesix director Strobeck buys $1M in company shares 03/29/22 Biodesix announces publication of data from GeneStrat NGS test studies BANR Banner Corp. $55.97 / +1.93 (+3.57%) 05/19/22 Banner Corp. says shareholders approved all proposals at annual meeting 03/04/22 Banner Corp. announces Copeland, Walsh appointed to board of directors 12/22/21 Banner announces 1.7M share repurchase agreement, 5% of its common stock ABST Absolute Software $8.16 / +0.25 (+3.16%) 06/06/22 Absolute Software announces new partnerships with ISVs 'leveraging' APaaS 03/07/22 Absolute Software CFO Steven Gatoff departs, Ron Fior named interim CFO ABST BANR CDW DGII SKIN XPOF ATRI CCMP DEN LNDC SKLZ TRNS TCX TBI SCHL SBEV EBET BEST BDSX CHKP CHEK EAR LVLU LMND ABST Absolute Software $8.16 / +0.25 (+3.16%) 05/11/22 BMO Capital Absolute Software price target lowered to C$12 from C$14 at BMO Capital 05/11/22 Canaccord Absolute Software price target lowered to $17 from $22 at Canaccord 02/09/22 BMO Capital Absolute Software price target lowered to C$14 from C$18.50 at BMO Capital 02/09/22 TD Securities TD Securities upgrades Absolute Software to Buy after 'another' beat and raise BANR Banner Corp. $55.97 / +1.93 (+3.57%) 06/17/22 Stephens Stephens upgrades Banner to Overweight as Street mismodels rate sensitivity 06/17/22 Stephens Banner Corp. upgraded to Overweight from Equal Weight at Stephens 01/24/22 Raymond James Banner Corp. price target raised to $72 from $68 at Raymond James 09/07/21 DA Davidson Banner Corp. downgraded to Neutral from Buy at DA Davidson CDW CDW $159.89 / +3.39 (+2.17%) 05/05/22 Evercore ISI CDW removed from 'TAP Outperform' list at Evercore ISI 04/18/22 Evercore ISI CDW added to 'TAP Outperform' list at Evercore ISI 04/14/22 Stifel CDW upgraded to Buy at Stifel following recent pullback 04/14/22 Stifel CDW upgraded to Buy from Hold at Stifel DGII Digi International $23.26 / +0.55 (+2.42%) 06/01/22 Stephens Digi International initiated with an Overweight at Stephens 02/03/22 Canaccord Digi International price target raised to $30 from $28 at Canaccord 11/11/21 Roth Capital Digi International price target raised to $33 from $28 at Roth Capital 11/11/21 Canaccord Digi International price target raised to $28 from $25 at Canaccord SKIN Beauty Health $11.78 / +0.52 (+4.62%) 05/11/22 Canaccord Beauty Health price target lowered to $22 from $27 at Canaccord 05/11/22 DA Davidson Beauty Health price target lowered to $24 from $35 at DA Davidson 05/11/22 Piper Sandler Beauty Health price target lowered to $24 from $26 at Piper Sandler 04/28/22 Piper Sandler Beauty Health price target lowered to $26 from $31 at Piper Sandler XPOF Xponential Fitness $12.85 / -0.02 (-0.16%) 06/13/22 Jefferies Jefferies names five top picks in lifestyle and growth platforms 03/14/22 Evercore ISI Evercore ISI starts Xponential Fitness at Outperform with $34 price target 03/14/22 Evercore ISI Xponential Fitness initiated with an Outperform at Evercore ISI 03/14/22 Baird Xponential Fitness price target raised to $28 from $26 at Baird ATRI Atrion $624.30 / -7.32 (-1.16%) CCMP CMC Materials $174.42 / +1.68 (+0.97%) 04/07/22 CL King CMC Materials downgraded to Neutral from Buy at CL King 04/07/22 CL King CMC Materials downgraded to Neutral from Buy at CL King 02/04/22 Mizuho CMC Materials downgraded to Neutral from Buy at Mizuho 12/17/21 Citi CMC Materials upgraded to Neutral after buyout at Citi DEN Denbury $67.13 / +3.42 (+5.37%) 05/24/22 Citi California Resources, Denbury may be takeout targets, says Citi 05/10/22 Citi Denbury initiated with a Buy at Citi 05/05/22 Stifel Denbury price target raised to $129 from $126 at Stifel 04/26/22 KeyBanc KeyBanc says Axios report positive for Plug Power, other fuel cell names LNDC Landec $10.11 / +0.36 (+3.69%) 04/06/22 Barrington Landec downgraded to Market Perform from Outperform at Barrington 09/30/21 Barrington Landec price target lowered to $12 from $14 at Barrington SKLZ Skillz $1.39 / +0.045 (+3.35%) 05/23/22 Citi Skillz downgraded to Neutral from Buy at Citi 03/01/22 Citi Skillz price target lowered to $5 from $9 at Citi 02/24/22 Stifel Skillz price target lowered to $3.50 from $16 at Stifel 02/24/22 Wedbush Skillz price target lowered to $7.50 from $25 at Wedbush TRNS Transcat $59.18 / +0.24 (+0.41%) 06/02/22 H.C. Wainwright Transcat price target lowered to $85 from $105 at H.C. Wainwright 05/26/22 Roth Capital Transcat price target lowered to $80 from $97 at Roth Capital 05/25/22 Craig-Hallum Transcat price target lowered to $81 from $94 at Craig-Hallum 02/03/22 Craig-Hallum Pullback in Transcat shares creates buying opportunity, says Craig-Hallum TCX Tucows $40.93 / -0.96 (-2.29%) TBI TrueBlue $16.83 / +0.585 (+3.60%) 05/26/22 BMO Capital TrueBlue downgraded to Market Perform from Outperform at BMO Capital 04/11/22 Sidoti TrueBlue reinstated with a Buy at Sidoti 10/26/21 Baird TrueBlue price target raised to $35 from $31 at Baird SCHL Scholastic $35.53 / +0.04 (+0.11%) SBEV Splash Beverage $2.06 / +0.24 (+13.19%) 04/25/22 EF Hutton Splash Beverage initiated with a Buy at EF Hutton EBET EBET $2.62 / -0.125 (-4.55%) 02/07/22 Needham Needham starts Esports Technologies at Buy on esports betting opportunity 02/07/22 Needham Esports Technologies initiated with a Buy at Needham BEST Best Inc. $1.22 / +0.01 (+0.83%) BDSX Biodesix $1.33 / -0.12 (-8.28%) 06/13/22 Canaccord Biodesix's Medicare coverage a meaningful milestone, says Canaccord 05/12/22 Canaccord Biodesix price target lowered to $7 from $10 at Canaccord 04/20/22 Cowen Biodesix initiated with an Outperform at Cowen 04/18/22 BTIG Biodesix price target lowered to $10 from $17 at BTIG CHKP Check Point $120.11 / +0.71 (+0.59%) 05/23/22 Jefferies Check Point price target lowered to $130 from $145 at Jefferies 04/28/22 Barclays Check Point price target lowered to $145 from $160 at Barclays 04/28/22 Credit Suisse Check Point price target raised to $115 from $105 at Credit Suisse 04/28/22 Wells Fargo Check Point price target lowered to $130 from $144 at Wells Fargo CHEK Check-Cap / + 02/07/22 Check-Cap upgraded to Buy from Neutral at Dawson James EAR Eargo $1.03 / -0.02 (-1.90%) 09/23/21 Fly Intel: Top five analyst downgrades 09/23/21 William Blair William Blair downgrades Eargo on 'multiple unknowns' from criminal probe 09/23/21 Wells Fargo Wells Fargo cuts Eargo to Equal Weight, slashes price target $10 from $52 09/23/21 William Blair Eargo downgraded to Market Perform from Outperform at William Blair LVLU Lulu's Fashion Lounge $12.27 / -0.4 (-3.16%) 06/10/22 BofA Lulu's Fashion Lounge downgraded to Neutral from Buy at BofA 01/14/22 Jefferies Jefferies still believes in strength of Lulu's model after management meetings 12/06/21 Cowen Cowen starts Lulu's Fashion Lounge with Outperform, affordable luxury brand 12/06/21 Baird Baird starts Lulu's Fashion Lounge with Outperform, sees attractive value LMND Lemonade $17.70 / +0.215 (+1.23%) 05/11/22 Oppenheimer Lemonade price target lowered to $30 from $45 at Oppenheimer 05/11/22 JMP Securities Lemonade price target lowered to $40 from $95 at JMP Securities 02/25/22 Barclays Lemonade price target lowered to $22 from $43 at Barclays 02/25/22 Oppenheimer Lemonade price target lowered to $45 from $85 at Oppenheimer XPOF TRNS TBI SKLZ SKIN SBEV LVLU LNDC LMND DGII DEN CHKP CHEK CDW CCMP BDSX BANR ABST XPOF Xponential Fitness $12.85 / -0.02 (-0.16%) 05/12/22 Xponential Fitness backs FY22 revenue $201M-$211M, consensus $209.85M 05/12/22 Xponential Fitness reports Q1 adjusted EPS (19c), consensus 12c 03/03/22 Xponential Fitness sees FY22 revenue $201M-$211M, consensus $199.54M 03/03/22 Xponential Fitness reports Q4 adjusted EPS (21c), consensus (14c) TRNS Transcat $59.18 / +0.24 (+0.41%) 05/23/22 Transcat sees FY22 adjusted EPS $2.03, consensus $1.72 02/01/22 Transcat reports Q3 EPS 21c, consensus 25c TBI TrueBlue $16.83 / +0.585 (+3.60%) 04/25/22 TrueBlue reports Q1 adjusted EPS 44c, consensus 35c 02/02/22 TrueBlue reports Q4 adjusted EPS 69c, consensus 43c SKLZ Skillz $1.39 / +0.045 (+3.35%) 05/04/22 Skillz sees FY22 revenue view $400M, consensus $399.24M 05/04/22 Skillz reports Q1 EPS (37c), consensus (18c) 02/23/22 Skillz sees FY22 revenue $400M, consensus $548.8M 02/23/22 Skillz reports Q4 EPS (25c), consensus (15c) SKIN Beauty Health $11.78 / +0.52 (+4.62%) 05/10/22 Beauty Health raises FY22 revenue view to $330M-$340M from $320M-$330M 05/10/22 Beauty Health reports Q1 EPS (13c), consensus (1c) 02/22/22 Beauty Health sees FY22 revenue $320M-$330M, consensus $314M 02/22/22 Beauty Health reports Q4 EPS (12c), consensus (2c) SBEV Splash Beverage $2.06 / +0.24 (+13.19%) 05/16/22 Splash Beverage reports Q1 revenue $4.1M vs $2.2M last year LVLU Lulu's Fashion Lounge $12.27 / -0.4 (-3.16%) 05/17/22 Lulu's Fashion Lounge sees FY22 revenue $490M-$500M, consensus $486.92M 05/17/22 Lulu's Fashion Lounge reports Q1 EPS 5c, consensus 5c 04/01/22 Lulu's Fashion Lounge sees FY22 revenue of $480M-$490M, consensus $472.06M 03/31/22 Lulu's Fashion Lounge reports Q4 EPS (3c), consensus (7c) LNDC Landec $10.11 / +0.36 (+3.69%) 04/05/22 Landec sees FY22 revenue $179M-$185M , consensus $182,01M 04/05/22 Landec reports Q3 EPS (8c), consensus 0c 01/05/22 Landec reports Q2 EPS ($1.30), consensus (7c) LMND Lemonade $17.70 / +0.215 (+1.23%) 05/09/22 Lemonade sees FY22 revenue $205M-$208M, consensus $216.49M 05/09/22 Lemonade sees Q2 revenue $46M-48M, consensus $51.83M 05/09/22 Lemonade reports Q1 EPS ($1.21), consensus ($1.43) 05/09/22 Notable companies reporting after market close DGII Digi International $23.26 / +0.55 (+2.42%) 05/04/22 Digi International sees Q3 EPS 37c-40c, consensus 37c 05/04/22 Digi International reports Q2 EPS 41c, consensus 32c 02/02/22 Digi International sees Q2 adjusted EPS 33c-37c, consensus 32c 02/02/22 Digi International reports Q1 adjusted EPS 36c, consensus 29c DEN Denbury $67.13 / +3.42 (+5.37%) 05/05/22 Denbury reports Q1 adjusted EPS $1.69, consensus $1.53 02/24/22 Denbury reports Q4 adjusted EPS 76c, consensus 70c CHKP Check Point $120.11 / +0.71 (+0.59%) 04/27/22 Check Point backs FY22 EPS view $6.90-$7.50, consensus $7.25 04/27/22 Check Point sees Q2 adjusted EPS $1.55-$1.65, consensus $1.65 04/27/22 Check Point reports Q1 EPS $1.57, consensus $1.54 02/03/22 Check Point sees FY22 EPS $6.90-$7.50, consensus $7.34 CHEK Check-Cap / + 04/07/22 Check-Cap reports Q4 EPS (8c), consensus (3c) CDW CDW $159.89 / +3.39 (+2.17%) 05/04/22 CDW reports Q1 EPS $2.20, consensus $2.01 02/09/22 CDW reports Q4 EPS $2.08, consensus $1.93 CCMP CMC Materials $174.42 / +1.68 (+0.97%) 05/04/22 CMC Materials sees Q3 revenue flat from Q2, consensus $317.4M 05/04/22 CMC Materials reports Q2 EPS $1.94, consensus $1.81 02/02/22 CMC Materials reports Q1 adjusted EPS $2.06, consensus $1.77 BDSX Biodesix $1.33 / -0.12 (-8.28%) 05/11/22 Biodesix still sees 2022 revenue $37.5M-$39.5M, consensus $38.41M 05/11/22 Biodesix reports Q1 EPS (50c), consensus (40c) 03/14/22 Biodesix sees FY22 revenue $37.5M-$39.5M, consensus $35.5M 03/14/22 Biodesix reports Q4 EPS (49c), consensus (49c) BANR Banner Corp. $55.97 / +1.93 (+3.57%) 04/20/22 Banner Corp. reports Q1 EPS $1.27, consensus $1.09 ABST Absolute Software $8.16 / +0.25 (+3.16%) 05/10/22 Absolute Software ups FY22 revenue view to $209.5M-$210.5M, consensus $207.35M 05/10/22 Absolute Software reports Q3 EPS (13c), consensus (10c) 02/08/22 Absolute Software raises FY22 revenue view to $206M-$208M, consensus $206.04M 02/08/22 Absolute Software reports Q2 EPS (10c), consensus (8c) 07 Apr 15 Feb 11 Nov 23 Jul LMND CHKP LMND Lemonade $17.70 / +0.215 (+1.23%) 02/14/22 Socially conscious sock maker Bombas exploring IPO, Bloomberg says CHKP Check Point $120.11 / +0.71 (+0.59%) 03/14/22 Israeli government sites crash in cyberattack, Haaretz reports XPOF TRNS TBI SKLZ SKIN SBEV LVLU LNDC EBET DEN CHKP CDW BDSX BANR XPOF Xponential Fitness $12.85 / -0.02 (-0.16%) 04/05/22 What You Missed On Wall Street This Morning 04/05/22 Fly Intel: Pre-market Movers 04/04/22 Fly Intel: After-Hours Movers TRNS Transcat $59.18 / +0.24 (+0.41%) 02/01/22 Fly Intel: After-Hours Movers TBI TrueBlue $16.83 / +0.585 (+3.60%) 05/26/22 What You Missed On Wall Street On Thursday 05/26/22 What You Missed On Wall Street This Morning SKLZ Skillz $1.39 / +0.045 (+3.35%) 02/23/22 Fly Intel: After-Hours Movers SKIN Beauty Health $11.78 / +0.52 (+4.62%) 06/17/22 Sell these stocks now, proven algorithm says 05/27/22 Sell these stocks now, proven algorithm says 05/13/22 Proven algorithm says sell these stocks now 02/23/22 What You Missed On Wall Street On Wednesday SBEV Splash Beverage $2.06 / +0.24 (+13.19%) 03/24/22 Meet Splash Beverage: Fly exclusive interview with CEO Robert Nistico 02/14/22 Fly Intel: After-Hours Movers LVLU Lulu's Fashion Lounge $12.27 / -0.4 (-3.16%) 05/17/22 Fly Intel: After-Hours Movers 04/01/22 What You Missed On Wall Street On Friday 04/01/22 What You Missed On Wall Street This Morning 04/01/22 Fly Intel: Pre-market Movers LNDC Landec $10.11 / +0.36 (+3.69%) 01/18/22 Fly Insider: Landec, AMC Entertainment among week's notable insider trades 01/05/22 Fly Intel: After-Hours Movers EBET EBET $2.62 / -0.125 (-4.55%) 02/07/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations DEN Denbury $67.13 / +3.42 (+5.37%) 05/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations CHKP Check Point $120.11 / +0.71 (+0.59%) 04/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/21/22 What You Missed On Wall Street On Monday 03/21/22 What You Missed On Wall Street This Morning 03/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations CDW CDW $159.89 / +3.39 (+2.17%) 04/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BDSX Biodesix $1.33 / -0.12 (-8.28%) 04/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/12/22 Fly Intel: Pre-market Movers 04/11/22 Fly Intel: After-Hours Movers BANR Banner Corp. $55.97 / +1.93 (+3.57%) 06/17/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/22/22 Energy, Power, & Renewables Conference 2022 06/28/22 Beauty Health Company (The) SKLZ SKIN SBEV LNDC LMND EBET EAR BEST BDSX BANR SKLZ Skillz $1.39 / +0.045 (+3.35%) 05/04/22 Skillz options imply 19.9% move in share price post-earnings 02/23/22 Skillz options imply 20.8% move in share price post-earnings 01/11/22 Skillz call volume above normal and directionally bullish SKIN Beauty Health $11.78 / +0.52 (+4.62%) 02/15/22 Beauth Health Company call buyer realizes 50% same-day gains 01/28/22 Beauth Health Company put volume heavy and directionally bearish SBEV Splash Beverage $2.06 / +0.24 (+13.19%) 02/23/22 Largest borrow rate increases among liquid names 01/21/22 One new option listing on January 21st LNDC Landec $10.11 / +0.36 (+3.69%) 01/05/22 Landec options imply 3.9% move in share price post-earnings LMND Lemonade $17.70 / +0.215 (+1.23%) 04/25/22 Lemonade call volume above normal and directionally bullish 04/05/22 Lemonade put volume heavy and directionally bearish 03/30/22 Lemonade put volume heavy and directionally bearish EBET EBET $2.62 / -0.125 (-4.55%) 06/14/22 Largest borrow rate increases among liquid names 02/04/22 Seven new option listings and one option delisting on February 4th EAR Eargo $1.03 / -0.02 (-1.90%) 03/07/22 Eargo options imply 12.6% move in share price post-earnings 02/10/22 Eargo options imply 10.7% move in share price post-earnings 02/03/22 Eargo options imply 9.5% move in share price post-earnings 01/27/22 Eargo options imply 14.5% move in share price post-earnings BEST Best Inc. $1.22 / +0.01 (+0.83%) 03/08/22 BEST Inc options imply 58.0% move in share price post-earnings BDSX Biodesix $1.33 / -0.12 (-8.28%) 04/12/22 Unusually active option classes on open April 12th BANR Banner Corp. $55.97 / +1.93 (+3.57%) 01/20/22 Banner Corp. options imply 5.9% move in share price post-earnings
Recommendations	Biodesix's Medicare coverage a meaningful milestone, says Canaccord » 07:20 06/13/22 06/13 07:20 06/13/22 07:20 BDSX Biodesix $1.91 / -0.14 (-6.83%) Canaccord analyst Kyle… Canaccord analyst Kyle Mikson noted Biodesix announced that WPS Government Health Administrators, the Medicare Administrative Contractor (MAC) with jurisdiction for BDSX's De Soto, Kansas, laboratory, had provided coverage for the Nodify CDT lung nodule test which is used by physicians to assess the risk of malignancy of a given lung nodule. The analyst believes broad coverage should drive adoption of the company's IQLung strategy for lung cancer patients and additionally, he believes that the new reimbursement could drive its margins higher over time. Mikson reiterated his Buy rating and $7 price target on Biodesix shares. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options BDSX Biodesix $1.91 / -0.14 (-6.83%) 06/07/22 Biodesix obtains Medicare coverage for Nodify CDT lung nodule test 06/03/22 Biodesix announces research agreement with top U.S. cancer center 04/11/22 Biodesix director Strobeck buys $1M in company shares 03/29/22 Biodesix announces publication of data from GeneStrat NGS test studies BDSX Biodesix $1.91 / -0.14 (-6.83%) 05/12/22 Canaccord Biodesix price target lowered to $7 from $10 at Canaccord 04/20/22 Cowen Biodesix initiated with an Outperform at Cowen 04/18/22 BTIG Biodesix price target lowered to $10 from $17 at BTIG 03/15/22 Canaccord Biodesix price target lowered to $10 from $18 at Canaccord BDSX Biodesix $1.91 / -0.14 (-6.83%) 05/11/22 Biodesix still sees 2022 revenue $37.5M-$39.5M, consensus $38.41M 05/11/22 Biodesix reports Q1 EPS (50c), consensus (40c) 03/14/22 Biodesix sees FY22 revenue $37.5M-$39.5M, consensus $35.5M 03/14/22 Biodesix reports Q4 EPS (49c), consensus (49c) BDSX Biodesix $1.91 / -0.14 (-6.83%) 04/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/12/22 Fly Intel: Pre-market Movers 04/11/22 Fly Intel: After-Hours Movers BDSX Biodesix $1.91 / -0.14 (-6.83%) 04/12/22 Unusually active option classes on open April 12th
Hot Stocks	Biodesix obtains Medicare coverage for Nodify CDT lung nodule test » 06:01 06/07/22 06/07 06:01 06/07/22 06:01 BDSX Biodesix $1.54 / +0.085 (+5.84%) Biodesix announced that… Biodesix announced that WPS Government Health Administrators, the Medicare Administrative Contractor with jurisdiction for Biodesix's De Soto, Kansas laboratory, has provided coverage for the Nodify CDT lung nodule test. The Nodify CDT test is a part of the Biodesix's blood-based Nodify Lung Nodule Risk Assessment testing strategy consisting of two tests to aid physicians in stratifying patients into distinct nodule management treatment pathways: diagnostic procedure or imaging surveillance. The Nodify CDT test helps identify patients with lung nodules that are likely malignant or higher risk of cancer, and the Nodify XL2 test conversely helps identify those that are likely benign or lower risk of cancer. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options BDSX Biodesix $1.54 / +0.085 (+5.84%) 06/03/22 Biodesix announces research agreement with top U.S. cancer center 04/11/22 Biodesix director Strobeck buys $1M in company shares 03/29/22 Biodesix announces publication of data from GeneStrat NGS test studies 03/07/22 Biodesix announces stock buyback for up to $50M with Lincoln Park Capital BDSX Biodesix $1.54 / +0.085 (+5.84%) 05/12/22 Canaccord Biodesix price target lowered to $7 from $10 at Canaccord 04/20/22 Cowen Biodesix initiated with an Outperform at Cowen 04/18/22 BTIG Biodesix price target lowered to $10 from $17 at BTIG 03/15/22 Canaccord Biodesix price target lowered to $10 from $18 at Canaccord BDSX Biodesix $1.54 / +0.085 (+5.84%) 05/11/22 Biodesix still sees 2022 revenue $37.5M-$39.5M, consensus $38.41M 05/11/22 Biodesix reports Q1 EPS (50c), consensus (40c) 03/14/22 Biodesix sees FY22 revenue $37.5M-$39.5M, consensus $35.5M 03/14/22 Biodesix reports Q4 EPS (49c), consensus (49c) BDSX Biodesix $1.54 / +0.085 (+5.84%) 04/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/12/22 Fly Intel: Pre-market Movers 04/11/22 Fly Intel: After-Hours Movers BDSX Biodesix $1.54 / +0.085 (+5.84%) 04/12/22 Unusually active option classes on open April 12th
Conference/Events	American Society of Clinical Oncology to hold annual meeting » 04:55 06/07/22 06/07 04:55 06/07/22 04:55 A Agilent $127.66 / -0.79 (-0.62%) , ALKS Alkermes $28.35 / -0.935 (-3.19%) , BDSX Biodesix $1.54 / +0.085 (+5.84%) , CSTL Castle Biosciences $21.53 / +2.405 (+12.58%) , ABBV AbbVie $146.65 / -0.56 (-0.38%) , ACET Adicet Bio $12.24 / +0.74 (+6.43%) , ACLX Arcellx $15.92 / +3.295 (+26.10%) , ADAP Adaptimmune $1.52 / -0.145 (-8.73%) , PFE Pfizer $53.23 / +0.03 (+0.06%) , PBYI Puma Biotechnology $2.39 / +0.05 (+2.14%) , ONCY Oncolytics $1.03 / -0.075 (-6.79%) , NVTA Invitae $2.93 / -0.085 (-2.82%) , NVS Novartis $88.68 / -0.43 (-0.48%) , NEO NeoGenomics $8.00 / -0.075 (-0.93%) , MTEM Molecular Templates / + , VBLT VBL Therapeutics $1.55 / -0.07 (-4.32%) , DSNKY Daiichi Sankyo $26.02 / +1.02 (+4.08%) , GLSI Greenwich LifeSciences $8.33 / -0.675 (-7.50%) , RTX Raytheon Technologies $97.25 / +0.865 (+0.90%) , SGEN Seagen $142.41 / +2.5 (+1.79%) , RHHBY Roche $41.23 / -0.32 (-0.77%) , EXEL Exelixis $18.80 / -0.26 (-1.36%) , FGEN FibroGen $9.52 / -0.43 (-4.32%) , CAH Cardinal Health $53.76 / -0.075 (-0.14%) , CBIO Catalyst Biosciences $1.15 / -0.08 (-6.50%) , ARVN Arvinas $42.76 / -1.46 (-3.30%) , AURA Aura Biosciences $17.44 / -0.15 (-0.85%) 2022 ASCO Annual Meeting… 2022 ASCO Annual Meeting to be held in Chicago on June 3-7. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VBLT SGEN RTX RHHBY PFE PBYI ONCY NVTA NVS NEO MTEM GLSI FGEN EXEL DSNKY CSTL CBIO CAH BDSX AURA ARVN ALKS ADAP ACLX ACET ABBV A VBLT VBL Therapeutics $1.55 / -0.07 (-4.32%) 05/17/22 VBL expects cash to be sufficient for at least a year beyond OVAL results 04/26/22 VBL Therapeutics receives FDA Fast Track designation for ofra-vec 03/31/22 VBL Therapeutics to host KOL seminar on ovarian cancer 03/08/22 VBL announces completion of enrollment in OVAL Phase 3 trial of ofra-vec SGEN Seagen $142.41 / +2.5 (+1.79%) 06/06/22 Seagen, Genmab present data from tisotumab vedotin clinical development program 06/03/22 Seagen says trial data show Adcetris, AVE-PC combo was well tolerated 05/23/22 Seagen gives topline results of Phase 2 trial of tucatinib/trastuzumab combo 05/16/22 Seagen CEO Clay Siegall resigns, Roger Dansey to continue as interim CEO RTX Raytheon Technologies $97.25 / +0.865 (+0.90%) 06/02/22 NASA selects Axiom, Collins Aerospace for space suit contract 05/27/22 Raytheon Technologies awarded $624.6M Army contract modification 05/26/22 Raytheon Technologies awarded $408.4M Navy contract modification 05/24/22 Raytheon Technologies awarded $217.12M Navy contract RHHBY Roche $41.23 / -0.32 (-0.77%) 06/01/22 Repare Therapeutics enters global license agreement with Rohce on RP-3500 05/31/22 FDA approves Roche's Evrysdi for use in babies under two months with SMA 05/26/22 Roche to present data demonstrating clinical benefit of Genentech's Glofitamab 05/25/22 Roche's Polivy combination approved by EC for previously untreated DLBCL PFE Pfizer $53.23 / +0.03 (+0.06%) 06/06/22 Pfizer to invest $120M at Michigan facility for Paxlovid production 06/05/22 Pfizer announces overall survival results from Phase 3 PALOMA-2 Trial of IBRANCE 06/02/22 Pfizer, Myovant Sciences announce FDA approval of sNDA for MYFEMBREE 06/01/22 Pfizer plans to exit ownership interest in Haleon PBYI Puma Biotechnology $2.39 / +0.05 (+2.14%) 06/05/22 Puma presents results from biliary tract cohort of Phase 2 SUMMIT basket trial 05/26/22 Puma Biotechnology to present two abstracts on neratinib at ASCO Meeting 02/15/22 Coherus Biosciences announces Paul Reider as chief commercial officer 01/12/22 Puma Biotechnology's NERLYNX included in NCCN guidelines for breast cancer ONCY Oncolytics $1.03 / -0.075 (-6.79%) 05/04/22 Oncolytics and SOLTI's pelareorep shows breast cancer prognosis efficacy in stud 04/14/22 Oncolytics' pelareorep shows anti-cancer potential in publication 04/08/22 Oncolytics reports 'positive' long-term survival data from ReoGlio trial 03/31/22 Oncolytics provides update on phase 1/2 GOBLET study NVTA Invitae $2.93 / -0.085 (-2.82%) 06/03/22 Invitae falls -14.4% 06/03/22 Invitae falls -11.5% 06/03/22 Invitae falls -6.9% 05/26/22 Invitae to present eight studies at ASCO NVS Novartis $88.68 / -0.43 (-0.48%) 06/06/22 Novartis says Tafinlar+Mekinist had 'unprecedented efficacy' in pediatric study 06/01/22 Knight Therapeutics assumes commercial activities for Exelon in Colombia 05/28/22 FDA approves Novartis' Kymriah CAR-T cell therapy for r/r follicular lymphoma 05/23/22 Insmed names Drayton Wise as Chief Commercial Officer NEO NeoGenomics $8.00 / -0.075 (-0.93%) 06/03/22 NeoGenomics receives CAP certfication in Suzhou China laboratory 05/16/22 NeoGenomics appoints Lynn Terault as interim CEO 05/16/22 NeoGenomics Chief Strategy and Corporate Development Officer to step down 05/16/22 NeoGenomics appoints Lynn Tetrault interim CEO MTEM Molecular Templates / + 06/06/22 Molecular Templates presents on PD-L1, HER2 programs at ASCO 05/12/22 Molecular Templates sees cash, investments funding operations to end of 2023 04/12/22 Molecular Templates reviews six poster presentations at AACR 2022 meeting 04/08/22 Molecular Templates to host webinar on immuno-oncology for solid tumors GLSI Greenwich LifeSciences $8.33 / -0.675 (-7.50%) 05/23/22 Greenwich LifeSciences to resume stock repurchase plan 05/23/22 Greenwich LifeSciences provides updates on Phase 3 clinical trial 04/21/22 Greenwich LifeSciences CEO buys $100K in common stock 02/01/22 Greenwich LifeSciences provides update on Phase III trial of Flamingo-01 FGEN FibroGen $9.52 / -0.43 (-4.32%) 05/09/22 FibroGen announces upcoming milestones 04/20/22 FibroGen announces completion of patient enrollment for ZEPHYRUS-1 12/20/21 FibroGen exercises exclusive license option for HiFiBiO's CCR8 program EXEL Exelixis $18.80 / -0.26 (-1.36%) 05/26/22 Exelixis announces results from multiple cohorts of COSMIC-021 trial 04/14/22 Exelixis starts 1st-in-human trial evaluating XL114 as a monotherapy for NHL 04/12/22 Vera Therapeutics appoints Morrissey as chairman of its board of directors 03/14/22 Exelixis does not intend to submit supplemental NDA to FDA for cabometyx DSNKY Daiichi Sankyo $26.02 / +1.02 (+4.08%) 05/05/22 AstraZeneca's Enhertu approved in U.S. in HER2-positive breast cancer 04/26/22 AstraZeneca's Enhertu granted breakthrough therapy designation in U.S. 03/07/22 Centessa expands management team with two new appointments 02/21/22 AstraZeneca reports 'positive high-level results' from DESTINY-Breast04 trial CSTL Castle Biosciences $21.53 / +2.405 (+12.58%) 05/24/22 Castle Biosciences announces results from TissueCypher Barrett's Esophagus study 05/19/22 Castle Biosciences' DecisionDx-SCC shows risk-stratification efficacy in study 05/10/22 Castle Biosciences teams with The Sun Bus to provide free skin cancer tests 04/27/22 Castle Biosciences announces publication of TissueCypher study CBIO Catalyst Biosciences $1.15 / -0.08 (-6.50%) 05/23/22 Catalyst Biosciences sells complement portfolio for $60M 03/15/22 Catalyst Biosciences regains full rights to CB 2782-PEG 02/17/22 Catalyst engages Perella Weinberg to assist in exploring strategic alternatives 01/25/22 Catalyst Biosciences receives RPDD for CB 4332 for treatment of CFID CAH Cardinal Health $53.76 / -0.075 (-0.14%) 06/02/22 Cardinal Health adds new distribution center in the Columbus Ohio area 05/11/22 Cardinal Health awarded $2.25B Defense Department contract modification 05/10/22 Cardinal Health raises quarterly dividend to 49.57c per share 05/03/22 Distributors agree to $518M opioid settlement With Washington state BDSX Biodesix $1.54 / +0.085 (+5.84%) 06/03/22 Biodesix announces research agreement with top U.S. cancer center 04/11/22 Biodesix director Strobeck buys $1M in company shares 03/29/22 Biodesix announces publication of data from GeneStrat NGS test studies 03/07/22 Biodesix announces stock buyback for up to $50M with Lincoln Park Capital AURA Aura Biosciences $17.44 / -0.15 (-0.85%) 05/26/22 Aura Biosciences announces publication of preclinical data on AU-011 at ASCO 05/03/22 Aura Biosciences presents preclinical data on AU-011's anti-tumor activity 03/21/22 Aura Biosciences: AU-011gets EU orphan drug designation for uveal melanoma ARVN Arvinas $42.76 / -1.46 (-3.30%) 05/09/22 Arvinas, GNS Healthcare announce neuroscience drug discovery collaboration 05/05/22 Arvinas announces anticipated milestones and expectations 02/17/22 Arvinas announces Phase 1, interim Phase 2 data for bavdegalutamide 02/17/22 Arvinas announces Phase 1, interim Phase 2 data for bavdegalutamide ALKS Alkermes $28.35 / -0.935 (-3.19%) 05/27/22 Sarissa condemns 'poor' corporate governance at Alkermes 04/27/22 Alkermes jumps 11% to $30.23 following Q1 beat 04/19/22 Alkermes begins arbitration regarding two license agreements with Janssen 02/17/22 Alkermes presents new data on nemvaleukin alfa monotherapy ADAP Adaptimmune $1.52 / -0.145 (-8.73%) 05/09/22 Adaptimmune names Joanna Brewer as chief scientific officer 05/09/22 Adaptimmune sees cash, equivalents funding operations into early 2024 05/04/22 Adaptimmune appoints Joanna Brewer as CSO 04/08/22 Adaptimmune presents MAGE-A4 expression data from screening protocol ACLX Arcellx $15.92 / +3.295 (+26.10%) 06/03/22 Arcellx reports 'positive' clinical data from Phase 1 CART-ddBCMA study 05/23/22 Arcellx appoints Michelle Gilson as CFO 05/10/22 Arcellx doses first patient in ACLX-001 Phase 1 clinical study of ARC-SparX 05/10/22 Arcellx Inc trading resumes ACET Adicet Bio $12.24 / +0.74 (+6.43%) 06/06/22 Adicet Bio outlines data from ADI-001 study at ASCO meeting 05/26/22 Adicet Bio's ADI-001 shows 67% response rate for NHL in Phase 1 trial 04/19/22 Adicet Bio gets FDA fast track designation for lead candidate ADI-001 ABBV AbbVie $146.65 / -0.56 (-0.38%) 06/03/22 Janssen says Imbruvica combo reduced lymphoma death by 25% in study 06/01/22 AbbVie: Phase 3 SELECT-AXIS 2 program met primary endpoint 05/27/22 AbbVie announces results from three trials evaluating upadacitinib published 05/25/22 West Virginia reaches $161M opioid settlement with Teva, AbbVie A Agilent $127.66 / -0.79 (-0.62%) 05/27/22 Agilent, APC announce liquid chromatography collaboration agreement 05/10/22 Agilent reports expanded CE-IVD mark in Europe for companion diagnostic 04/05/22 Agilent expands CE-IVD marking in EU for PD-L1 IHC 28-8 pharmDx 02/28/22 Singular Genomics partners with Agilent for NGS Target Enrichment products A ALKS BDSX CSTL ABBV ACET ACLX ADAP PFE PBYI ONCY NVTA NVS NEO MTEM VBLT DSNKY GLSI RTX SGEN RHHBY EXEL FGEN CAH CBIO ARVN AURA A Agilent $127.66 / -0.79 (-0.62%) 06/03/22 Cowen Agilent premium valuation remains warranted, says Cowen 06/02/22 KeyBanc Agilent price target lowered to $155 from $195 at KeyBanc 05/25/22 Baird Agilent price target raised to $161 from $155 at Baird 05/16/22 Citi Citi opens 'positive catalyst watch' on Agilent into earnings ALKS Alkermes $28.35 / -0.935 (-3.19%) 04/28/22 Mizuho Alkermes price target raised to $36 from $35 at Mizuho 04/28/22 H.C. Wainwright Alkermes price target raised to $32 from $30 at H.C. Wainwright 04/27/22 Stifel Alkermes price target raised to $27 from $24 at Stifel 04/20/22 Goldman Sachs Alkermes initiated with a Buy at Goldman Sachs BDSX Biodesix $1.54 / +0.085 (+5.84%) 05/12/22 Canaccord Biodesix price target lowered to $7 from $10 at Canaccord 04/20/22 Cowen Biodesix initiated with an Outperform at Cowen 04/18/22 BTIG Biodesix price target lowered to $10 from $17 at BTIG 03/15/22 Canaccord Biodesix price target lowered to $10 from $18 at Canaccord CSTL Castle Biosciences $21.53 / +2.405 (+12.58%) 05/19/22 Baird Baird says final LCD for test 'incrementally positive' for Castle Biosciences 05/10/22 Canaccord Castle Biosciences price target lowered to $65 from $80 at Canaccord 05/10/22 Baird Castle Biosciences price target lowered to $44 from $50 at Baird 05/09/22 BTIG Castle Biosciences transferred with a Buy at BTIG ABBV AbbVie $146.65 / -0.56 (-0.38%) 05/23/22 SVB Securities AbbVie initiated with an Underperform at SVB Leerink 05/13/22 Piper Sandler Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler 05/06/22 Daiwa AbbVie downgraded to Neutral from Outperform at Daiwa 05/03/22 Morgan Stanley Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure ACET Adicet Bio $12.24 / +0.74 (+6.43%) 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 03/17/22 JMP Securities Adicet Bio price target lowered to $21 from $30 at JMP Securities 03/08/22 Truist Adicet Bio initiated with a Buy at Truist 03/04/22 Jefferies Adicet Bio initiated with a Buy at Jefferies ACLX Arcellx $15.92 / +3.295 (+26.10%) 03/02/22 Barclays Arcellx initiated with an Overweight at Barclays 03/01/22 SVB Securities Arcellx initiated with an Outperform at SVB Leerink 03/01/22 BofA Arcellx initiated with a Buy at BofA 03/01/22 BofA Arcellx initiated with a Buy at BofA ADAP Adaptimmune $1.52 / -0.145 (-8.73%) 11/11/21 Roth Capital Roth says Adaptimmune synovial sarcoma trial hitting goal appears 'a certainty' PFE Pfizer $53.23 / +0.03 (+0.06%) 06/03/22 Oppenheimer Turning Point Therapeutics downgraded to Perform from Outperform at Oppenheimer 05/31/22 Evercore ISI Enanta upgraded to In Line from Underperform at Evercore ISI 05/25/22 Piper Sandler Piper Sandler says Ventyx Biosciences' VTX002 could produce superior efficacy 05/23/22 Piper Sandler Biohaven price target lowered to $149 from $170 at Piper Sandler PBYI Puma Biotechnology $2.39 / +0.05 (+2.14%) 05/06/22 H.C. Wainwright Puma Biotechnology price target lowered to $12 from $14 at H.C. Wainwright 09/28/21 Fly Intel: Top five analyst upgrades 09/28/21 Citi Puma Biotechnology upgraded to Buy after 40% selloff at Citi 09/27/21 Citi Puma Biotechnology upgraded to Buy from Neutral at Citi ONCY Oncolytics $1.03 / -0.075 (-6.79%) 01/27/22 Canaccord Oncolytics price target lowered to $6 from $7 at Canaccord NVTA Invitae $2.93 / -0.085 (-2.82%) 06/02/22 Piper Sandler Invitae initiated with an Underweight at Piper Sandler 05/04/22 Raymond James Invitae price target lowered to $8.50 from $10.50 at Raymond James 02/28/22 Raymond James Invitae price target lowered to $15 from $36 at Raymond James 11/09/21 Wells Fargo Invitae price target lowered to $25 from $35 at Wells Fargo NVS Novartis $88.68 / -0.43 (-0.48%) 05/13/22 Piper Sandler Point Biopharma price target lowered to $14 from $17 at Piper Sandler 05/13/22 Jefferies Roche downgraded to Hold from Buy at Jefferies 05/09/22 Wolfe Research Novartis downgraded to Peer Perform from Outperform at Wolfe Research NEO NeoGenomics $8.00 / -0.075 (-0.93%) 06/02/22 Piper Sandler NeoGenomics initiated with an Overweight at Piper Sandler 03/29/22 Cowen NeoGenomics price target lowered to $24 from $42 at Cowen 03/29/22 BTIG NeoGenomics price target lowered to $28 from $35 at BTIG 03/29/22 SVB Securities NeoGenomics price target lowered to $20 from $45 at SVB Leerink MTEM Molecular Templates / + 05/27/22 BofA Molecular Templates downgraded to Underperform from Buy at BofA 05/13/22 Stifel Molecular Templates price target lowered to $9 from $11 at Stifel 03/30/22 Barclays Molecular Templates price target lowered to $4.50 from $8 at Barclays VBLT VBL Therapeutics $1.55 / -0.07 (-4.32%) 04/28/22 Chardan VBL Therapeutics initiated with a Buy at Chardan 08/30/21 Roth Capital Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes 06/15/21 Roth Capital Roth does not see material change to VBL readout timelines DSNKY Daiichi Sankyo $26.02 / +1.02 (+4.08%) 10/27/21 SVB Securities Seagen price target raised to $200 from $190 at SVB Leerink GLSI Greenwich LifeSciences $8.33 / -0.675 (-7.50%) 09/01/21 H.C. Wainwright Greenwich LifeSciences initiated with a Buy at H.C. Wainwright RTX Raytheon Technologies $97.25 / +0.865 (+0.90%) 04/27/22 Argus Raytheon Technologies price target raised to $112 from $100 at Argus 04/27/22 Cowen Raytheon Technologies price target raised to $120 from $115 at Cowen 04/08/22 RBC Capital Raytheon Technologies initiated with an Outperform at RBC Capital 03/29/22 Jefferies Northrop among biggest beneficiaries of DoD budget request, says Jefferies SGEN Seagen $142.41 / +2.5 (+1.79%) 04/08/22 Roth Capital Bicycle reported 'very strong' side-effect profile, says Roth Capital 04/08/22 Cantor Fitzgerald Bicycle Therapeutics' BT8009 abstract 'very positive,' says Cantor Fitzgerald 02/24/22 Piper Sandler Seagen's tisotumab vedotin shows 'modest signal of activity,' says Piper Sandler 02/16/22 JMP Securities Seagen price target lowered to $142 from $201 at JMP Securities RHHBY Roche $41.23 / -0.32 (-0.77%) 06/02/22 Piper Sandler Piper ups Repare Therapeutics target after 'great deal' with Roche 05/19/22 Credit Suisse Roche price target lowered to CHF 350 from CHF 370 at Credit Suisse 05/12/22 Morgan Stanley Roche price target lowered to CHF 370 from CHF 395 at Morgan Stanley EXEL Exelixis $18.80 / -0.26 (-1.36%) 05/19/22 Piper Sandler Exelixis sold off on Cabometyx patent trial comments, says Piper Sandler 05/19/22 Truist Exelixis should be bought on dip caused by '776 patent worries, says Truist 05/12/22 Jefferies Exelixis could approach $26-$28 if it settles or wins MSN trial, says Jefferies 03/14/22 Piper Sandler Exelixis price target lowered to $30 from $34 at Piper Sandler FGEN FibroGen $9.52 / -0.43 (-4.32%) 09/22/21 Fly Intel: Top five analyst downgrades 09/22/21 Goldman Sachs FibroGen downgraded to Sell from Neutral at Goldman Sachs 08/20/21 Raymond James FibroGen upgraded to Market Perform from Underperform at Raymond James 08/20/21 Raymond James FibroGen upgraded to Market Perform from Underperform at Raymond James CAH Cardinal Health $53.76 / -0.075 (-0.14%) 05/26/22 Barclays Cardinal Health downgraded to Equal Weight from Overweight at Barclays 05/18/22 Evercore ISI Evercore upgrades Cardinal Health to Outperform on undervalued Medical segment 05/18/22 Evercore ISI Cardinal Health upgraded to Outperform from In Line at Evercore ISI 04/12/22 Morgan Stanley McKesson price target raised to $370 from $292 at Morgan Stanley CBIO Catalyst Biosciences $1.15 / -0.08 (-6.50%) 05/23/22 Piper Sandler Piper Sandler remains bullish on Catalyst after sale of complement portfolio 03/31/22 Piper Sandler Piper says 'stick it out' with Catalyst Biosciences exploring options 11/12/21 JonesTrading Catalyst Biosciences downgraded to Hold from Buy at JonesTrading 11/12/21 Piper Sandler Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler ARVN Arvinas $42.76 / -1.46 (-3.30%) 05/23/22 Piper Sandler Arvinas price target lowered to $76 from $116 at Piper Sandler 05/09/22 Wedbush Wedbush downgrades Arvinas to Neutral, cuts price target to $43 05/09/22 Wedbush Arvinas downgraded to Neutral from Outperform at Wedbush 05/06/22 Cantor Fitzgerald Arvinas assumed with an Overweight at Cantor Fitzgerald AURA Aura Biosciences $17.44 / -0.15 (-0.85%) 11/23/21 SVB Securities Aura Biosciences initiated with an Outperform at SVB Leerink 11/23/21 BTIG Aura Biosciences initiated with a Buy at BTIG 11/23/21 Evercore ISI Evercore starts Aura Biosciences at Outperform with $35 price target 11/23/21 Cowen Aura Biosciences initiated with an Outperform at Cowen VBLT SGEN RTX RHHBY PFE PBYI ONCY NVTA NVS NEO MTEM FGEN EXEL CSTL CBIO CAH BDSX AURA ARVN ALKS ADAP ACLX ACET ABBV A VBLT VBL Therapeutics $1.55 / -0.07 (-4.32%) 05/17/22 VBL Therapeutics reports Q1 EPS (13c), consensus (11c) 03/23/22 VBL Therapeutics reports FY21 EPS (45c), consensus (41c) SGEN Seagen $142.41 / +2.5 (+1.79%) 04/28/22 Seagen sees FY22 total revenue $1.665B-$1.745B, consensus $1.78B 04/28/22 Seagen reports Q1 EPS (74c), consensus ($1.00) 02/10/22 Seagen sees FY22 total revenue $1.67B-$1.75B, consensus $2.16B 02/09/22 Seagen reports Q4 EPS (95c), consensus (83c) RTX Raytheon Technologies $97.25 / +0.865 (+0.90%) 04/26/22 Raytheon Technologies backs FY22 adjusted EPS view $4.60-$4.80, consensus $4.79 04/26/22 Raytheon Technologies reports Q1 adjusted EPS $1.15, consensus $1.01 04/25/22 Notable companies reporting before tomorrow's open RHHBY Roche $41.23 / -0.32 (-0.77%) 04/25/22 Roche reports Q1 group sales CHF 16.445B vs. CHF 14.93B last year 02/03/22 Roche sees FY22 core earnings growing in low- to mid-single digit range 02/03/22 Roche reports 2021 core EPS CHF 19.81 vs CHF 19.16 PFE Pfizer $53.23 / +0.03 (+0.06%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open PBYI Puma Biotechnology $2.39 / +0.05 (+2.14%) 05/05/22 Puma Biotechnology reports Q1 EPS (1c), consensus (17c) 03/03/22 Puma Biotechnology reports Q4 EPS 21c, consensus (9c) ONCY Oncolytics $1.03 / -0.075 (-6.79%) 05/05/22 Oncolytics reports Q1 EPS 12c, consensus (11c) 03/03/22 Oncolytics reports Q4 EPS (14c), consensus (10c) NVTA Invitae $2.93 / -0.085 (-2.82%) 05/03/22 Invitae reports Q1 non-GAAP EPS 78c, consensus (76c) 02/24/22 Invitae sees 2022 revenue $640M, consensus $638.69M 02/24/22 Invitae reports Q4 non-GAAP EPS (81c), consensus (73c) NVS Novartis $88.68 / -0.43 (-0.48%) 04/26/22 Novartis sees 2022 core operating income to grow mid single digit 04/26/22 Novartis reports Q1 core EPS $1.46, consensus $1.46 02/02/22 Novartis sees 2022 sales, core operating income up mid single digit 02/02/22 Novartis reports Q4 core EPS $1.40 vs. $1.34 last year NEO NeoGenomics $8.00 / -0.075 (-0.93%) 04/27/22 NeoGenomics reports Q1 adjusted EPS (20c), consensus (23c) 04/26/22 Notable companies reporting before tomorrow's open 03/28/22 NeoGenomics now sees Q1 revenue below $118M-$120M range, consensus $119.16M MTEM Molecular Templates / + 05/13/22 Molecular Templates reports Q1 EPS (38c), consensus (47c) 03/28/22 Molecular Templates reports Q4 EPS (18c), consensus (40c) FGEN FibroGen $9.52 / -0.43 (-4.32%) 05/09/22 FibroGen reports Q1 EPS (68c), consensus (83c) 02/28/22 FibroGen reports Q EPS ($1.45), consensus (66c) EXEL Exelixis $18.80 / -0.26 (-1.36%) 05/10/22 Exelixis sees FY22 revenue $1.525B-$1.625B, consensus $1.64B 05/10/22 Exelixis reports Q1 adjusted EPS 26c, consensus 14c 02/17/22 Exelixis reports Q4 adjusted EPS 35c, consensus 6c 01/09/22 Exelixis sees preliminary Q4 net product revenue $300M CSTL Castle Biosciences $21.53 / +2.405 (+12.58%) 05/09/22 Castle Biosciences raises FY22 revenue view to $118M-$123M from $115M-$120M 05/09/22 Castle Biosciences reports Q1 EPS (97c), consensus (71c) 02/28/22 Castle Biosciences sees FY22 revenue $115M-$120M, consensus $113.54M 02/28/22 Castle Biosciences reports Q4 EPS (25c), consensus (47c) CBIO Catalyst Biosciences $1.15 / -0.08 (-6.50%) 05/09/22 Catalyst Biosciences reports Q1 EPS (46c), consensus (44c) 03/31/22 Catalyst Biosciences reports Q4 EPS (65c), consensus (59c) CAH Cardinal Health $53.76 / -0.075 (-0.14%) 05/05/22 Cardinal Health narrows FY21 EPS view to $5.15-$5.25 from $5.15-$5.50 05/05/22 Cardinal Health reports Q3 EPS $1.45, consensus $1.52 02/03/22 Cardinal Health cuts FY22 EPS view to $5.15-$5.50 from $5.60-$5.90 02/03/22 Cardinal Health reports Q2 EPS $1.27, consensus $1.23 BDSX Biodesix $1.54 / +0.085 (+5.84%) 05/11/22 Biodesix still sees 2022 revenue $37.5M-$39.5M, consensus $38.41M 05/11/22 Biodesix reports Q1 EPS (50c), consensus (40c) 03/14/22 Biodesix sees FY22 revenue $37.5M-$39.5M, consensus $35.5M 03/14/22 Biodesix reports Q4 EPS (49c), consensus (49c) AURA Aura Biosciences $17.44 / -0.15 (-0.85%) 03/23/22 Aura Biosciences reports FY21 EPS ($8.95), consensus ($4.41) ARVN Arvinas $42.76 / -1.46 (-3.30%) 05/05/22 Arvinas reports Q1 EPS ($1.20), consensus (89c) 02/28/22 Arvinas reports Q4 EPS ($1.00), consensus (79c) ALKS Alkermes $28.35 / -0.935 (-3.19%) 04/27/22 Alkermes reiterates 2022 financial expectations given in February 04/27/22 Alkermes reports Q1 EPS 12c, consensus 1c 02/16/22 Alkermes updates long-term profitability targets for Invega royalty removal 02/16/22 Alkermes sees FY22 adjusted EPS (18c)-0c, consensus 35c ADAP Adaptimmune $1.52 / -0.145 (-8.73%) 05/09/22 Adaptimmune reports Q1 EPS (5c), consensus (22c) 03/14/22 Adaptimmune reports Q4 EPS (4c), consensus 14c ACLX Arcellx $15.92 / +3.295 (+26.10%) 05/12/22 Arcellx reports Q1 EPS ($1.56), consensus (64c) 03/24/22 Arcellx reports Q4 EPS ($39.85) vs. ($28.27) a year ago ACET Adicet Bio $12.24 / +0.74 (+6.43%) 06/06/22 Notable companies reporting after market close 05/12/22 Adicet Bio reports Q1 EPS (12c), consensus (18c) 03/15/22 Adicet Bio reports Q4 EPS (47c), consensus (42c) ABBV AbbVie $146.65 / -0.56 (-0.38%) 04/29/22 AbbVie sees FY22 revenue $59.4B, consensus $60.22B 04/29/22 AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50 04/29/22 AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20 04/29/22 AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14 A Agilent $127.66 / -0.79 (-0.62%) 05/24/22 Agilent raises FY22 EPS view to $4.86-$4.93, consensus $4.60 05/24/22 Agilent sees Q3 EPS $1.20-$1.22, consensus $1.12 05/24/22 Agilent reports Q2 EPS $1.13, consensus $1.06 02/22/22 Agilent raises FY22 EPS view to $4.80-$4.90, consensus $4.27 04 Feb 08 Dec 29 Oct RTX RHHBY PFE NVS CAH ABBV RTX Raytheon Technologies $97.25 / +0.865 (+0.90%) 05/06/22 Manufacturers to boost reliance on U.S. firms for 3D printing, AP reports 05/03/22 Biden to visit facility where Lockheed is making Javelin weapon, CNBC reports 04/19/22 Lockheed Martin in talks with Pentagon on weapons to Ukraine, WSJ reports 04/13/22 Defense contractors to meet with Pentagon to discuss Ukraine aid, FT reports RHHBY Roche $41.23 / -0.32 (-0.77%) 02/24/22 Drugmakers criticize Medicare proposal on Biogen's Alzheimer's drug, WSJ says 02/09/22 Credit Suisse shareholders to block moves to extend Schwan's tenure, FT reports 12/20/21 Roche's Genentech to license rights to Lineage eye drug, WSJ reports PFE Pfizer $53.23 / +0.03 (+0.06%) 06/02/22 Pfizer ask FDA to authorize three doses of vaccine for kids under 5, WSJ report 05/31/22 Pfizer's Paxlovid becomes leading pandemic pill, WSJ reports 05/25/22 Pfizer CEO tells CNBC he 'wouldn't worry much' about monkeypox 05/25/22 Pfizer to sell 23 products at lower pirces to poorer countries, WSJ reports NVS Novartis $88.68 / -0.43 (-0.48%) 02/10/22 FDA expresses concerns about quality of China-developed drugs, WSJ reports 02/02/22 Novartis CEO says all options are open on Sandoz, FT reports CAH Cardinal Health $53.76 / -0.075 (-0.14%) 02/01/22 J&J, distributors to pay $590M to settle tribes' opioid claims, Bloomberg says ABBV AbbVie $146.65 / -0.56 (-0.38%) 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports SGEN RTX RHHBY PFE PBYI NVTA NVS NEO EXEL CSTL CBIO CAH BDSX ARVN ALKS ADAP ACLX ACET ABBV A SGEN Seagen $142.41 / +2.5 (+1.79%) 02/10/22 Wall Street in Fives - Must Read Lists for Thursday 02/10/22 Wall Street in Fives - Must Read Lists at Midday 02/09/22 Fly Intel: After-Hours Movers RTX Raytheon Technologies $97.25 / +0.865 (+0.90%) 04/26/22 Fly Intel: Pre-market Movers 02/28/22 Fly Intel: Pre-market Movers 02/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 01/25/22 Fly Intel: Pre-market Movers RHHBY Roche $41.23 / -0.32 (-0.77%) 06/02/22 What You Missed On Wall Street This Morning 01/13/22 Meet Prothena: Fly exclusive interview with CEO Gene Kinney PFE Pfizer $53.23 / +0.03 (+0.06%) 05/24/22 What You Missed On Wall Street This Morning 05/10/22 What You Missed On Wall Street This Morning PBYI Puma Biotechnology $2.39 / +0.05 (+2.14%) 01/13/22 Fly Intel: Pre-market Movers NVTA Invitae $2.93 / -0.085 (-2.82%) 06/03/22 What You Missed On Wall Street This Morning NVS Novartis $88.68 / -0.43 (-0.48%) 01/19/22 Meet Sangamo: Fly exclusive interview with CEO Sandy Macrae, COO Mark McClung 01/18/22 Fly Intel: Pre-market Movers 12/16/21 Fly Intel: Pre-market Movers NEO NeoGenomics $8.00 / -0.075 (-0.93%) 05/06/22 Proven algorithm says sell these stocks now 04/29/22 Proven algorithm says sell these stocks now 04/27/22 Fly Intel: Pre-market Movers 03/29/22 What You Missed On Wall Street On Tuesday EXEL Exelixis $18.80 / -0.26 (-1.36%) 03/14/22 Fly Intel: After-Hours Movers 02/18/22 What You Missed On Wall Street On Friday 02/18/22 What You Missed On Wall Street This Morning CSTL Castle Biosciences $21.53 / +2.405 (+12.58%) 04/04/22 Fly Intel: After-Hours Movers CBIO Catalyst Biosciences $1.15 / -0.08 (-6.50%) 05/09/22 What You Missed On Wall Street This Morning CAH Cardinal Health $53.76 / -0.075 (-0.14%) 05/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/12/22 What You Missed On Wall Street On Tuesday 04/12/22 What You Missed On Wall Street This Morning 04/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BDSX Biodesix $1.54 / +0.085 (+5.84%) 04/12/22 Fly Intel: Pre-market Movers 04/11/22 Fly Intel: After-Hours Movers ARVN Arvinas $42.76 / -1.46 (-3.30%) 05/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ALKS Alkermes $28.35 / -0.935 (-3.19%) 04/20/22 What You Missed On Wall Street On Wednesday 04/20/22 What You Missed On Wall Street This Morning 04/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ADAP Adaptimmune $1.52 / -0.145 (-8.73%) 03/14/22 What You Missed On Wall Street On Monday 03/14/22 What You Missed On Wall Street This Morning ACLX Arcellx $15.92 / +3.295 (+26.10%) 03/26/22 Opening Day: AN2 Therapeutics rises in public debut after upsized IPO 02/05/22 Opening Day: Arcellx raises $124M in Wall Street debut ACET Adicet Bio $12.24 / +0.74 (+6.43%) 06/06/22 Fly Intel: After-Hours Movers 05/26/22 Fly Intel: After-Hours Movers 03/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ABBV AbbVie $146.65 / -0.56 (-0.38%) 05/23/22 What You Missed On Wall Street On Monday 05/23/22 What You Missed On Wall Street This Morning 05/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/10/22 What You Missed On Wall Street On Tuesday A Agilent $127.66 / -0.79 (-0.62%) 05/24/22 Fly Intel: After-Hours Movers 03/28/22 Fly Insider: GameStop, Agilent among this week's notable insider trades 06/17/22 Biopharma;Biotech 07/14/22 Biotech/Biopharma 06/07/22 Global Industrials & Transportation Conference 06/08/22 Global Healthcare Conference 09/07/22 2022 Wells Fargo Healthcare Conference 08/06/22 Extended PDUFA Date for MYFEMBREE 06/10/22 Roche 06/14/22 Puma Biotechnology, Inc. 06/15/22 Aura Biosciences , Inc. 06/16/22 Arvinas, Inc. 06/16/22 FibroGen, Inc. 09/19/22 Novartis RTX PFE NVTA NEO CBIO BDSX ABBV A RTX Raytheon Technologies $97.25 / +0.865 (+0.90%) 03/21/22 Raytheon Technologies call volume above normal and directionally bullish 02/23/22 Unusually active option classes on open February 23rd 01/10/22 Raytheon Technologies put volume heavy and directionally bearish 01/04/22 Raytheon Technologies call volume above normal and directionally bullish PFE Pfizer $53.23 / +0.03 (+0.06%) 05/20/22 Early notable gainers among liquid option names on May 20th 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish NVTA Invitae $2.93 / -0.085 (-2.82%) 05/03/22 Invitae options imply 14.1% move in share price post-earnings 02/24/22 Invitae options imply 14.1% move in share price post-earnings NEO NeoGenomics $8.00 / -0.075 (-0.93%) 05/04/22 Largest borrow rate increases among liquid names CBIO Catalyst Biosciences $1.15 / -0.08 (-6.50%) 05/23/22 Unusually active option classes on open May 23rd BDSX Biodesix $1.54 / +0.085 (+5.84%) 04/12/22 Unusually active option classes on open April 12th ABBV AbbVie $146.65 / -0.56 (-0.38%) 04/29/22 Unusually active option classes on open April 29th 02/24/22 AbbVie put volume heavy and directionally bearish 01/24/22 AbbVie put volume heavy and directionally bearish A Agilent $127.66 / -0.79 (-0.62%) 05/24/22 Agilent options imply 4.7% move in share price post-earnings
Syndicate	Biodesix files to sell 2.88M shares of common stock for holders 17:26 06/06/22 06/06 17:26 06/06/22 17:26 BDSX Biodesix $1.54 / +0.085 (+5.84%) ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options BDSX Biodesix $1.54 / +0.085 (+5.84%) 06/03/22 Biodesix announces research agreement with top U.S. cancer center 04/11/22 Biodesix director Strobeck buys $1M in company shares 03/29/22 Biodesix announces publication of data from GeneStrat NGS test studies 03/07/22 Biodesix announces stock buyback for up to $50M with Lincoln Park Capital BDSX Biodesix $1.54 / +0.085 (+5.84%) 05/12/22 Canaccord Biodesix price target lowered to $7 from $10 at Canaccord 04/20/22 Cowen Biodesix initiated with an Outperform at Cowen 04/18/22 BTIG Biodesix price target lowered to $10 from $17 at BTIG 03/15/22 Canaccord Biodesix price target lowered to $10 from $18 at Canaccord BDSX Biodesix $1.54 / +0.085 (+5.84%) 05/11/22 Biodesix still sees 2022 revenue $37.5M-$39.5M, consensus $38.41M 05/11/22 Biodesix reports Q1 EPS (50c), consensus (40c) 03/14/22 Biodesix sees FY22 revenue $37.5M-$39.5M, consensus $35.5M 03/14/22 Biodesix reports Q4 EPS (49c), consensus (49c) BDSX Biodesix $1.54 / +0.085 (+5.84%) 04/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/12/22 Fly Intel: Pre-market Movers 04/11/22 Fly Intel: After-Hours Movers BDSX Biodesix $1.54 / +0.085 (+5.84%) 04/12/22 Unusually active option classes on open April 12th
Conference/Events	American Society of Clinical Oncology to hold annual meeting » 10:01 06/06/22 06/06 10:01 06/06/22 10:01 A Agilent $129.14 / +0.69 (+0.54%) , ALKS Alkermes $29.06 / -0.225 (-0.77%) , BDSX Biodesix $1.45 / -0.005 (-0.34%) , CSTL Castle Biosciences $20.66 / +1.535 (+8.03%) , ABBV AbbVie $146.29 / -0.92 (-0.62%) , ACET Adicet Bio $11.21 / -0.29 (-2.52%) , ACLX Arcellx $13.44 / +0.815 (+6.46%) , ADAP Adaptimmune $1.63 / -0.03 (-1.81%) , PFE Pfizer $53.19 / -0.01 (-0.02%) , PBYI Puma Biotechnology $2.37 / +0.025 (+1.07%) , ONCY Oncolytics $1.08 / -0.025 (-2.26%) , NVTA Invitae $2.94 / -0.075 (-2.49%) , NVS Novartis $89.27 / +0.16 (+0.18%) , NEO NeoGenomics $8.11 / +0.04 (+0.50%) , MTEM Molecular Templates $1.03 / +0.0523 (+5.35%) , VBLT VBL Therapeutics $1.62 / + (+0.00%) , DSNKY Daiichi Sankyo $25.00 / -0.4 (-1.57%) , GLSI Greenwich LifeSciences $8.89 / -0.11 (-1.22%) , RTX Raytheon Technologies $96.73 / +0.345 (+0.36%) , SGEN Seagen $143.37 / +3.46 (+2.47%) , RHHBY Roche $41.55 / -0.7 (-1.66%) , EXEL Exelixis $18.95 / -0.105 (-0.55%) , FGEN FibroGen $9.86 / -0.09 (-0.90%) , CAH Cardinal Health $53.94 / +0.1 (+0.19%) , CBIO Catalyst Biosciences $1.34 / +0.11 (+8.94%) , ARVN Arvinas $45.33 / +1.11 (+2.51%) , AURA Aura Biosciences $17.57 / -0.02 (-0.11%) 2022 ASCO Annual Meeting… 2022 ASCO Annual Meeting to be held in Chicago on June 3-7. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VBLT SGEN RTX RHHBY PFE PBYI ONCY NVTA NVS NEO MTEM GLSI FGEN EXEL DSNKY CSTL CBIO CAH BDSX AURA ARVN ALKS ADAP ACLX ACET ABBV A VBLT VBL Therapeutics $1.62 / + (+0.00%) 05/17/22 VBL expects cash to be sufficient for at least a year beyond OVAL results 04/26/22 VBL Therapeutics receives FDA Fast Track designation for ofra-vec 03/31/22 VBL Therapeutics to host KOL seminar on ovarian cancer 03/08/22 VBL announces completion of enrollment in OVAL Phase 3 trial of ofra-vec SGEN Seagen $143.37 / +3.46 (+2.47%) 06/03/22 Seagen says trial data show Adcetris, AVE-PC combo was well tolerated 05/23/22 Seagen gives topline results of Phase 2 trial of tucatinib/trastuzumab combo 05/16/22 Seagen CEO Clay Siegall resigns, Roger Dansey to continue as interim CEO 05/09/22 Seagen CEO Clay Siegall takes leave of absence, Roger Dansey named interim CEO RTX Raytheon Technologies $96.73 / +0.345 (+0.36%) 06/02/22 NASA selects Axiom, Collins Aerospace for space suit contract 05/27/22 Raytheon Technologies awarded $624.6M Army contract modification 05/26/22 Raytheon Technologies awarded $408.4M Navy contract modification 05/24/22 Raytheon Technologies awarded $217.12M Navy contract RHHBY Roche $41.55 / -0.7 (-1.66%) 06/01/22 Repare Therapeutics enters global license agreement with Rohce on RP-3500 05/31/22 FDA approves Roche's Evrysdi for use in babies under two months with SMA 05/26/22 Roche to present data demonstrating clinical benefit of Genentech's Glofitamab 05/25/22 Roche's Polivy combination approved by EC for previously untreated DLBCL PFE Pfizer $53.19 / -0.01 (-0.02%) 06/05/22 Pfizer announces overall survival results from Phase 3 PALOMA-2 Trial of IBRANCE 06/02/22 Pfizer, Myovant Sciences announce FDA approval of sNDA for MYFEMBREE 06/01/22 Pfizer plans to exit ownership interest in Haleon 06/01/22 GlaxoSmithKline provides update on demerger of consumer heathcare business PBYI Puma Biotechnology $2.37 / +0.025 (+1.07%) 06/05/22 Puma presents results from biliary tract cohort of Phase 2 SUMMIT basket trial 05/26/22 Puma Biotechnology to present two abstracts on neratinib at ASCO Meeting 02/15/22 Coherus Biosciences announces Paul Reider as chief commercial officer 01/12/22 Puma Biotechnology's NERLYNX included in NCCN guidelines for breast cancer ONCY Oncolytics $1.08 / -0.025 (-2.26%) 05/04/22 Oncolytics and SOLTI's pelareorep shows breast cancer prognosis efficacy in stud 04/14/22 Oncolytics' pelareorep shows anti-cancer potential in publication 04/08/22 Oncolytics reports 'positive' long-term survival data from ReoGlio trial 03/31/22 Oncolytics provides update on phase 1/2 GOBLET study NVTA Invitae $2.94 / -0.075 (-2.49%) 06/03/22 Invitae falls -14.4% 06/03/22 Invitae falls -11.5% 06/03/22 Invitae falls -6.9% 05/26/22 Invitae to present eight studies at ASCO NVS Novartis $89.27 / +0.16 (+0.18%) 06/06/22 Novartis says Tafinlar+Mekinist had 'unprecedented efficacy' in pediatric study 06/01/22 Knight Therapeutics assumes commercial activities for Exelon in Colombia 05/28/22 FDA approves Novartis' Kymriah CAR-T cell therapy for r/r follicular lymphoma 05/23/22 Insmed names Drayton Wise as Chief Commercial Officer NEO NeoGenomics $8.11 / +0.04 (+0.50%) 06/03/22 NeoGenomics receives CAP certfication in Suzhou China laboratory 05/16/22 NeoGenomics appoints Lynn Terault as interim CEO 05/16/22 NeoGenomics Chief Strategy and Corporate Development Officer to step down 05/16/22 NeoGenomics appoints Lynn Tetrault interim CEO MTEM Molecular Templates $1.03 / +0.0523 (+5.35%) 06/06/22 Molecular Templates presents on PD-L1, HER2 programs at ASCO 05/12/22 Molecular Templates sees cash, investments funding operations to end of 2023 04/12/22 Molecular Templates reviews six poster presentations at AACR 2022 meeting 04/08/22 Molecular Templates to host webinar on immuno-oncology for solid tumors GLSI Greenwich LifeSciences $8.89 / -0.11 (-1.22%) 05/23/22 Greenwich LifeSciences to resume stock repurchase plan 05/23/22 Greenwich LifeSciences provides updates on Phase 3 clinical trial 04/21/22 Greenwich LifeSciences CEO buys $100K in common stock 02/01/22 Greenwich LifeSciences provides update on Phase III trial of Flamingo-01 FGEN FibroGen $9.86 / -0.09 (-0.90%) 05/09/22 FibroGen announces upcoming milestones 04/20/22 FibroGen announces completion of patient enrollment for ZEPHYRUS-1 12/20/21 FibroGen exercises exclusive license option for HiFiBiO's CCR8 program EXEL Exelixis $18.95 / -0.105 (-0.55%) 05/26/22 Exelixis announces results from multiple cohorts of COSMIC-021 trial 04/14/22 Exelixis starts 1st-in-human trial evaluating XL114 as a monotherapy for NHL 04/12/22 Vera Therapeutics appoints Morrissey as chairman of its board of directors 03/14/22 Exelixis does not intend to submit supplemental NDA to FDA for cabometyx DSNKY Daiichi Sankyo $25.00 / -0.4 (-1.57%) 05/05/22 AstraZeneca's Enhertu approved in U.S. in HER2-positive breast cancer 04/26/22 AstraZeneca's Enhertu granted breakthrough therapy designation in U.S. 03/07/22 Centessa expands management team with two new appointments 02/21/22 AstraZeneca reports 'positive high-level results' from DESTINY-Breast04 trial CSTL Castle Biosciences $20.66 / +1.535 (+8.03%) 05/24/22 Castle Biosciences announces results from TissueCypher Barrett's Esophagus study 05/19/22 Castle Biosciences' DecisionDx-SCC shows risk-stratification efficacy in study 05/10/22 Castle Biosciences teams with The Sun Bus to provide free skin cancer tests 04/27/22 Castle Biosciences announces publication of TissueCypher study CBIO Catalyst Biosciences $1.34 / +0.11 (+8.94%) 05/23/22 Catalyst Biosciences sells complement portfolio for $60M 03/15/22 Catalyst Biosciences regains full rights to CB 2782-PEG 02/17/22 Catalyst engages Perella Weinberg to assist in exploring strategic alternatives 01/25/22 Catalyst Biosciences receives RPDD for CB 4332 for treatment of CFID CAH Cardinal Health $53.94 / +0.1 (+0.19%) 06/02/22 Cardinal Health adds new distribution center in the Columbus Ohio area 05/11/22 Cardinal Health awarded $2.25B Defense Department contract modification 05/10/22 Cardinal Health raises quarterly dividend to 49.57c per share 05/03/22 Distributors agree to $518M opioid settlement With Washington state BDSX Biodesix $1.45 / -0.005 (-0.34%) 06/03/22 Biodesix announces research agreement with top U.S. cancer center 04/11/22 Biodesix director Strobeck buys $1M in company shares 03/29/22 Biodesix announces publication of data from GeneStrat NGS test studies 03/07/22 Biodesix announces stock buyback for up to $50M with Lincoln Park Capital AURA Aura Biosciences $17.57 / -0.02 (-0.11%) 05/26/22 Aura Biosciences announces publication of preclinical data on AU-011 at ASCO 05/03/22 Aura Biosciences presents preclinical data on AU-011's anti-tumor activity 03/21/22 Aura Biosciences: AU-011gets EU orphan drug designation for uveal melanoma ARVN Arvinas $45.33 / +1.11 (+2.51%) 05/09/22 Arvinas, GNS Healthcare announce neuroscience drug discovery collaboration 05/05/22 Arvinas announces anticipated milestones and expectations 02/17/22 Arvinas announces Phase 1, interim Phase 2 data for bavdegalutamide 02/17/22 Arvinas announces Phase 1, interim Phase 2 data for bavdegalutamide ALKS Alkermes $29.06 / -0.225 (-0.77%) 05/27/22 Sarissa condemns 'poor' corporate governance at Alkermes 04/27/22 Alkermes jumps 11% to $30.23 following Q1 beat 04/19/22 Alkermes begins arbitration regarding two license agreements with Janssen 02/17/22 Alkermes presents new data on nemvaleukin alfa monotherapy ADAP Adaptimmune $1.63 / -0.03 (-1.81%) 05/09/22 Adaptimmune names Joanna Brewer as chief scientific officer 05/09/22 Adaptimmune sees cash, equivalents funding operations into early 2024 05/04/22 Adaptimmune appoints Joanna Brewer as CSO 04/08/22 Adaptimmune presents MAGE-A4 expression data from screening protocol ACLX Arcellx $13.44 / +0.815 (+6.46%) 06/03/22 Arcellx reports 'positive' clinical data from Phase 1 CART-ddBCMA study 05/23/22 Arcellx appoints Michelle Gilson as CFO 05/10/22 Arcellx doses first patient in ACLX-001 Phase 1 clinical study of ARC-SparX 05/10/22 Arcellx Inc trading resumes ACET Adicet Bio $11.21 / -0.29 (-2.52%) 06/06/22 Adicet Bio outlines data from ADI-001 study at ASCO meeting 05/26/22 Adicet Bio's ADI-001 shows 67% response rate for NHL in Phase 1 trial 04/19/22 Adicet Bio gets FDA fast track designation for lead candidate ADI-001 12/06/21 Adicet Bio trading resumes ABBV AbbVie $146.29 / -0.92 (-0.62%) 06/03/22 Janssen says Imbruvica combo reduced lymphoma death by 25% in study 06/01/22 AbbVie: Phase 3 SELECT-AXIS 2 program met primary endpoint 05/27/22 AbbVie announces results from three trials evaluating upadacitinib published 05/25/22 West Virginia reaches $161M opioid settlement with Teva, AbbVie A Agilent $129.14 / +0.69 (+0.54%) 05/27/22 Agilent, APC announce liquid chromatography collaboration agreement 05/10/22 Agilent reports expanded CE-IVD mark in Europe for companion diagnostic 04/05/22 Agilent expands CE-IVD marking in EU for PD-L1 IHC 28-8 pharmDx 02/28/22 Singular Genomics partners with Agilent for NGS Target Enrichment products A ALKS BDSX CSTL ABBV ACET ACLX ADAP PFE PBYI ONCY NVTA NVS NEO MTEM VBLT DSNKY GLSI RTX SGEN RHHBY EXEL FGEN CAH CBIO ARVN AURA A Agilent $129.14 / +0.69 (+0.54%) 06/03/22 Cowen Agilent premium valuation remains warranted, says Cowen 06/02/22 KeyBanc Agilent price target lowered to $155 from $195 at KeyBanc 05/25/22 Baird Agilent price target raised to $161 from $155 at Baird 05/16/22 Citi Citi opens 'positive catalyst watch' on Agilent into earnings ALKS Alkermes $29.06 / -0.225 (-0.77%) 04/28/22 Mizuho Alkermes price target raised to $36 from $35 at Mizuho 04/28/22 H.C. Wainwright Alkermes price target raised to $32 from $30 at H.C. Wainwright 04/27/22 Stifel Alkermes price target raised to $27 from $24 at Stifel 04/20/22 Goldman Sachs Alkermes initiated with a Buy at Goldman Sachs BDSX Biodesix $1.45 / -0.005 (-0.34%) 05/12/22 Canaccord Biodesix price target lowered to $7 from $10 at Canaccord 04/20/22 Cowen Biodesix initiated with an Outperform at Cowen 04/18/22 BTIG Biodesix price target lowered to $10 from $17 at BTIG 03/15/22 Canaccord Biodesix price target lowered to $10 from $18 at Canaccord CSTL Castle Biosciences $20.66 / +1.535 (+8.03%) 05/19/22 Baird Baird says final LCD for test 'incrementally positive' for Castle Biosciences 05/10/22 Canaccord Castle Biosciences price target lowered to $65 from $80 at Canaccord 05/10/22 Baird Castle Biosciences price target lowered to $44 from $50 at Baird 05/09/22 BTIG Castle Biosciences transferred with a Buy at BTIG ABBV AbbVie $146.29 / -0.92 (-0.62%) 05/23/22 SVB Securities AbbVie initiated with an Underperform at SVB Leerink 05/13/22 Piper Sandler Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler 05/06/22 Daiwa AbbVie downgraded to Neutral from Outperform at Daiwa 05/03/22 Morgan Stanley Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure ACET Adicet Bio $11.21 / -0.29 (-2.52%) 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 03/17/22 JMP Securities Adicet Bio price target lowered to $21 from $30 at JMP Securities 03/08/22 Truist Adicet Bio initiated with a Buy at Truist 03/04/22 Jefferies Adicet Bio initiated with a Buy at Jefferies ACLX Arcellx $13.44 / +0.815 (+6.46%) 03/02/22 Barclays Arcellx initiated with an Overweight at Barclays 03/01/22 SVB Securities Arcellx initiated with an Outperform at SVB Leerink 03/01/22 BofA Arcellx initiated with a Buy at BofA 03/01/22 BofA Arcellx initiated with a Buy at BofA ADAP Adaptimmune $1.63 / -0.03 (-1.81%) 11/11/21 Roth Capital Roth says Adaptimmune synovial sarcoma trial hitting goal appears 'a certainty' PFE Pfizer $53.19 / -0.01 (-0.02%) 06/03/22 Oppenheimer Turning Point Therapeutics downgraded to Perform from Outperform at Oppenheimer 05/31/22 Evercore ISI Enanta upgraded to In Line from Underperform at Evercore ISI 05/25/22 Piper Sandler Piper Sandler says Ventyx Biosciences' VTX002 could produce superior efficacy 05/23/22 Piper Sandler Biohaven price target lowered to $149 from $170 at Piper Sandler PBYI Puma Biotechnology $2.37 / +0.025 (+1.07%) 05/06/22 H.C. Wainwright Puma Biotechnology price target lowered to $12 from $14 at H.C. Wainwright 09/28/21 Fly Intel: Top five analyst upgrades 09/28/21 Citi Puma Biotechnology upgraded to Buy after 40% selloff at Citi 09/27/21 Citi Puma Biotechnology upgraded to Buy from Neutral at Citi ONCY Oncolytics $1.08 / -0.025 (-2.26%) 01/27/22 Canaccord Oncolytics price target lowered to $6 from $7 at Canaccord NVTA Invitae $2.94 / -0.075 (-2.49%) 06/02/22 Piper Sandler Invitae initiated with an Underweight at Piper Sandler 05/04/22 Raymond James Invitae price target lowered to $8.50 from $10.50 at Raymond James 02/28/22 Raymond James Invitae price target lowered to $15 from $36 at Raymond James 11/09/21 Wells Fargo Invitae price target lowered to $25 from $35 at Wells Fargo NVS Novartis $89.27 / +0.16 (+0.18%) 05/13/22 Piper Sandler Point Biopharma price target lowered to $14 from $17 at Piper Sandler 05/13/22 Jefferies Roche downgraded to Hold from Buy at Jefferies 05/09/22 Wolfe Research Novartis downgraded to Peer Perform from Outperform at Wolfe Research NEO NeoGenomics $8.11 / +0.04 (+0.50%) 06/02/22 Piper Sandler NeoGenomics initiated with an Overweight at Piper Sandler 03/29/22 Cowen NeoGenomics price target lowered to $24 from $42 at Cowen 03/29/22 BTIG NeoGenomics price target lowered to $28 from $35 at BTIG 03/29/22 SVB Securities NeoGenomics price target lowered to $20 from $45 at SVB Leerink MTEM Molecular Templates $1.03 / +0.0523 (+5.35%) 05/27/22 BofA Molecular Templates downgraded to Underperform from Buy at BofA 05/13/22 Stifel Molecular Templates price target lowered to $9 from $11 at Stifel 03/30/22 Barclays Molecular Templates price target lowered to $4.50 from $8 at Barclays VBLT VBL Therapeutics $1.62 / + (+0.00%) 04/28/22 Chardan VBL Therapeutics initiated with a Buy at Chardan 08/30/21 Roth Capital Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes 06/15/21 Roth Capital Roth does not see material change to VBL readout timelines DSNKY Daiichi Sankyo $25.00 / -0.4 (-1.57%) 10/27/21 SVB Securities Seagen price target raised to $200 from $190 at SVB Leerink GLSI Greenwich LifeSciences $8.89 / -0.11 (-1.22%) 09/01/21 H.C. Wainwright Greenwich LifeSciences initiated with a Buy at H.C. Wainwright RTX Raytheon Technologies $96.73 / +0.345 (+0.36%) 04/27/22 Argus Raytheon Technologies price target raised to $112 from $100 at Argus 04/27/22 Cowen Raytheon Technologies price target raised to $120 from $115 at Cowen 04/08/22 RBC Capital Raytheon Technologies initiated with an Outperform at RBC Capital 03/29/22 Jefferies Northrop among biggest beneficiaries of DoD budget request, says Jefferies SGEN Seagen $143.37 / +3.46 (+2.47%) 04/08/22 Roth Capital Bicycle reported 'very strong' side-effect profile, says Roth Capital 04/08/22 Cantor Fitzgerald Bicycle Therapeutics' BT8009 abstract 'very positive,' says Cantor Fitzgerald 02/24/22 Piper Sandler Seagen's tisotumab vedotin shows 'modest signal of activity,' says Piper Sandler 02/16/22 JMP Securities Seagen price target lowered to $142 from $201 at JMP Securities RHHBY Roche $41.55 / -0.7 (-1.66%) 06/02/22 Piper Sandler Piper ups Repare Therapeutics target after 'great deal' with Roche 05/19/22 Credit Suisse Roche price target lowered to CHF 350 from CHF 370 at Credit Suisse 05/12/22 Morgan Stanley Roche price target lowered to CHF 370 from CHF 395 at Morgan Stanley EXEL Exelixis $18.95 / -0.105 (-0.55%) 05/19/22 Piper Sandler Exelixis sold off on Cabometyx patent trial comments, says Piper Sandler 05/19/22 Truist Exelixis should be bought on dip caused by '776 patent worries, says Truist 05/12/22 Jefferies Exelixis could approach $26-$28 if it settles or wins MSN trial, says Jefferies 03/14/22 Piper Sandler Exelixis price target lowered to $30 from $34 at Piper Sandler FGEN FibroGen $9.86 / -0.09 (-0.90%) 09/22/21 Fly Intel: Top five analyst downgrades 09/22/21 Goldman Sachs FibroGen downgraded to Sell from Neutral at Goldman Sachs 08/20/21 Raymond James FibroGen upgraded to Market Perform from Underperform at Raymond James 08/20/21 Raymond James FibroGen upgraded to Market Perform from Underperform at Raymond James CAH Cardinal Health $53.94 / +0.1 (+0.19%) 05/26/22 Barclays Cardinal Health downgraded to Equal Weight from Overweight at Barclays 05/18/22 Evercore ISI Evercore upgrades Cardinal Health to Outperform on undervalued Medical segment 05/18/22 Evercore ISI Cardinal Health upgraded to Outperform from In Line at Evercore ISI 04/12/22 Morgan Stanley McKesson price target raised to $370 from $292 at Morgan Stanley CBIO Catalyst Biosciences $1.34 / +0.11 (+8.94%) 05/23/22 Piper Sandler Piper Sandler remains bullish on Catalyst after sale of complement portfolio 03/31/22 Piper Sandler Piper says 'stick it out' with Catalyst Biosciences exploring options 11/12/21 JonesTrading Catalyst Biosciences downgraded to Hold from Buy at JonesTrading 11/12/21 Piper Sandler Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler ARVN Arvinas $45.33 / +1.11 (+2.51%) 05/23/22 Piper Sandler Arvinas price target lowered to $76 from $116 at Piper Sandler 05/09/22 Wedbush Wedbush downgrades Arvinas to Neutral, cuts price target to $43 05/09/22 Wedbush Arvinas downgraded to Neutral from Outperform at Wedbush 05/06/22 Cantor Fitzgerald Arvinas assumed with an Overweight at Cantor Fitzgerald AURA Aura Biosciences $17.57 / -0.02 (-0.11%) 11/23/21 SVB Securities Aura Biosciences initiated with an Outperform at SVB Leerink 11/23/21 BTIG Aura Biosciences initiated with a Buy at BTIG 11/23/21 Evercore ISI Evercore starts Aura Biosciences at Outperform with $35 price target 11/23/21 Cowen Aura Biosciences initiated with an Outperform at Cowen VBLT SGEN RTX RHHBY PFE PBYI ONCY NVTA NVS NEO MTEM FGEN EXEL CSTL CBIO CAH BDSX AURA ARVN ALKS ADAP ACLX ACET ABBV A VBLT VBL Therapeutics $1.62 / + (+0.00%) 05/17/22 VBL Therapeutics reports Q1 EPS (13c), consensus (11c) 03/23/22 VBL Therapeutics reports FY21 EPS (45c), consensus (41c) SGEN Seagen $143.37 / +3.46 (+2.47%) 04/28/22 Seagen sees FY22 total revenue $1.665B-$1.745B, consensus $1.78B 04/28/22 Seagen reports Q1 EPS (74c), consensus ($1.00) 02/10/22 Seagen sees FY22 total revenue $1.67B-$1.75B, consensus $2.16B 02/09/22 Seagen reports Q4 EPS (95c), consensus (83c) RTX Raytheon Technologies $96.73 / +0.345 (+0.36%) 04/26/22 Raytheon Technologies backs FY22 adjusted EPS view $4.60-$4.80, consensus $4.79 04/26/22 Raytheon Technologies reports Q1 adjusted EPS $1.15, consensus $1.01 04/25/22 Notable companies reporting before tomorrow's open RHHBY Roche $41.55 / -0.7 (-1.66%) 04/25/22 Roche reports Q1 group sales CHF 16.445B vs. CHF 14.93B last year 02/03/22 Roche sees FY22 core earnings growing in low- to mid-single digit range 02/03/22 Roche reports 2021 core EPS CHF 19.81 vs CHF 19.16 PFE Pfizer $53.19 / -0.01 (-0.02%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open PBYI Puma Biotechnology $2.37 / +0.025 (+1.07%) 05/05/22 Puma Biotechnology reports Q1 EPS (1c), consensus (17c) 03/03/22 Puma Biotechnology reports Q4 EPS 21c, consensus (9c) ONCY Oncolytics $1.08 / -0.025 (-2.26%) 05/05/22 Oncolytics reports Q1 EPS 12c, consensus (11c) 03/03/22 Oncolytics reports Q4 EPS (14c), consensus (10c) NVTA Invitae $2.94 / -0.075 (-2.49%) 05/03/22 Invitae reports Q1 non-GAAP EPS 78c, consensus (76c) 02/24/22 Invitae sees 2022 revenue $640M, consensus $638.69M 02/24/22 Invitae reports Q4 non-GAAP EPS (81c), consensus (73c) NVS Novartis $89.27 / +0.16 (+0.18%) 04/26/22 Novartis sees 2022 core operating income to grow mid single digit 04/26/22 Novartis reports Q1 core EPS $1.46, consensus $1.46 02/02/22 Novartis sees 2022 sales, core operating income up mid single digit 02/02/22 Novartis reports Q4 core EPS $1.40 vs. $1.34 last year NEO NeoGenomics $8.11 / +0.04 (+0.50%) 04/27/22 NeoGenomics reports Q1 adjusted EPS (20c), consensus (23c) 04/26/22 Notable companies reporting before tomorrow's open 03/28/22 NeoGenomics now sees Q1 revenue below $118M-$120M range, consensus $119.16M MTEM Molecular Templates $1.03 / +0.0523 (+5.35%) 05/13/22 Molecular Templates reports Q1 EPS (38c), consensus (47c) 03/28/22 Molecular Templates reports Q4 EPS (18c), consensus (40c) FGEN FibroGen $9.86 / -0.09 (-0.90%) 05/09/22 FibroGen reports Q1 EPS (68c), consensus (83c) 02/28/22 FibroGen reports Q EPS ($1.45), consensus (66c) EXEL Exelixis $18.95 / -0.105 (-0.55%) 05/10/22 Exelixis sees FY22 revenue $1.525B-$1.625B, consensus $1.64B 05/10/22 Exelixis reports Q1 adjusted EPS 26c, consensus 14c 02/17/22 Exelixis reports Q4 adjusted EPS 35c, consensus 6c 01/09/22 Exelixis sees preliminary Q4 net product revenue $300M CSTL Castle Biosciences $20.66 / +1.535 (+8.03%) 05/09/22 Castle Biosciences raises FY22 revenue view to $118M-$123M from $115M-$120M 05/09/22 Castle Biosciences reports Q1 EPS (97c), consensus (71c) 02/28/22 Castle Biosciences sees FY22 revenue $115M-$120M, consensus $113.54M 02/28/22 Castle Biosciences reports Q4 EPS (25c), consensus (47c) CBIO Catalyst Biosciences $1.34 / +0.11 (+8.94%) 05/09/22 Catalyst Biosciences reports Q1 EPS (46c), consensus (44c) 03/31/22 Catalyst Biosciences reports Q4 EPS (65c), consensus (59c) CAH Cardinal Health $53.94 / +0.1 (+0.19%) 05/05/22 Cardinal Health narrows FY21 EPS view to $5.15-$5.25 from $5.15-$5.50 05/05/22 Cardinal Health reports Q3 EPS $1.45, consensus $1.52 02/03/22 Cardinal Health cuts FY22 EPS view to $5.15-$5.50 from $5.60-$5.90 02/03/22 Cardinal Health reports Q2 EPS $1.27, consensus $1.23 BDSX Biodesix $1.45 / -0.005 (-0.34%) 05/11/22 Biodesix still sees 2022 revenue $37.5M-$39.5M, consensus $38.41M 05/11/22 Biodesix reports Q1 EPS (50c), consensus (40c) 03/14/22 Biodesix sees FY22 revenue $37.5M-$39.5M, consensus $35.5M 03/14/22 Biodesix reports Q4 EPS (49c), consensus (49c) AURA Aura Biosciences $17.57 / -0.02 (-0.11%) 03/23/22 Aura Biosciences reports FY21 EPS ($8.95), consensus ($4.41) ARVN Arvinas $45.33 / +1.11 (+2.51%) 05/05/22 Arvinas reports Q1 EPS ($1.20), consensus (89c) 02/28/22 Arvinas reports Q4 EPS ($1.00), consensus (79c) ALKS Alkermes $29.06 / -0.225 (-0.77%) 04/27/22 Alkermes reiterates 2022 financial expectations given in February 04/27/22 Alkermes reports Q1 EPS 12c, consensus 1c 02/16/22 Alkermes updates long-term profitability targets for Invega royalty removal 02/16/22 Alkermes sees FY22 adjusted EPS (18c)-0c, consensus 35c ADAP Adaptimmune $1.63 / -0.03 (-1.81%) 05/09/22 Adaptimmune reports Q1 EPS (5c), consensus (22c) 03/14/22 Adaptimmune reports Q4 EPS (4c), consensus 14c ACLX Arcellx $13.44 / +0.815 (+6.46%) 05/12/22 Arcellx reports Q1 EPS ($1.56), consensus (64c) 03/24/22 Arcellx reports Q4 EPS ($39.85) vs. ($28.27) a year ago ACET Adicet Bio $11.21 / -0.29 (-2.52%) 05/12/22 Adicet Bio reports Q1 EPS (12c), consensus (18c) 03/15/22 Adicet Bio reports Q4 EPS (47c), consensus (42c) ABBV AbbVie $146.29 / -0.92 (-0.62%) 04/29/22 AbbVie sees FY22 revenue $59.4B, consensus $60.22B 04/29/22 AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50 04/29/22 AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20 04/29/22 AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14 A Agilent $129.14 / +0.69 (+0.54%) 05/24/22 Agilent raises FY22 EPS view to $4.86-$4.93, consensus $4.60 05/24/22 Agilent sees Q3 EPS $1.20-$1.22, consensus $1.12 05/24/22 Agilent reports Q2 EPS $1.13, consensus $1.06 02/22/22 Agilent raises FY22 EPS view to $4.80-$4.90, consensus $4.27 04 Feb 08 Dec 29 Oct RTX RHHBY PFE NVS CAH ABBV RTX Raytheon Technologies $96.73 / +0.345 (+0.36%) 05/06/22 Manufacturers to boost reliance on U.S. firms for 3D printing, AP reports 05/03/22 Biden to visit facility where Lockheed is making Javelin weapon, CNBC reports 04/19/22 Lockheed Martin in talks with Pentagon on weapons to Ukraine, WSJ reports 04/13/22 Defense contractors to meet with Pentagon to discuss Ukraine aid, FT reports RHHBY Roche $41.55 / -0.7 (-1.66%) 02/24/22 Drugmakers criticize Medicare proposal on Biogen's Alzheimer's drug, WSJ says 02/09/22 Credit Suisse shareholders to block moves to extend Schwan's tenure, FT reports 12/20/21 Roche's Genentech to license rights to Lineage eye drug, WSJ reports PFE Pfizer $53.19 / -0.01 (-0.02%) 06/02/22 Pfizer ask FDA to authorize three doses of vaccine for kids under 5, WSJ report 05/31/22 Pfizer's Paxlovid becomes leading pandemic pill, WSJ reports 05/25/22 Pfizer CEO tells CNBC he 'wouldn't worry much' about monkeypox 05/25/22 Pfizer to sell 23 products at lower pirces to poorer countries, WSJ reports NVS Novartis $89.27 / +0.16 (+0.18%) 02/10/22 FDA expresses concerns about quality of China-developed drugs, WSJ reports 02/02/22 Novartis CEO says all options are open on Sandoz, FT reports 12/06/21 Novartis at work on pan-coronavirus oral treatment, Reuters reports CAH Cardinal Health $53.94 / +0.1 (+0.19%) 02/01/22 J&J, distributors to pay $590M to settle tribes' opioid claims, Bloomberg says ABBV AbbVie $146.29 / -0.92 (-0.62%) 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports SGEN RTX RHHBY PFE PBYI NVTA NVS NEO EXEL CSTL CBIO CAH BDSX ARVN ALKS ADAP ACLX ACET ABBV A SGEN Seagen $143.37 / +3.46 (+2.47%) 02/10/22 Wall Street in Fives - Must Read Lists for Thursday 02/10/22 Wall Street in Fives - Must Read Lists at Midday 02/09/22 Fly Intel: After-Hours Movers RTX Raytheon Technologies $96.73 / +0.345 (+0.36%) 04/26/22 Fly Intel: Pre-market Movers 02/28/22 Fly Intel: Pre-market Movers 02/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 01/25/22 Fly Intel: Pre-market Movers RHHBY Roche $41.55 / -0.7 (-1.66%) 06/02/22 What You Missed On Wall Street This Morning 01/13/22 Meet Prothena: Fly exclusive interview with CEO Gene Kinney PFE Pfizer $53.19 / -0.01 (-0.02%) 05/24/22 What You Missed On Wall Street This Morning 05/10/22 What You Missed On Wall Street This Morning PBYI Puma Biotechnology $2.37 / +0.025 (+1.07%) 01/13/22 Fly Intel: Pre-market Movers NVTA Invitae $2.94 / -0.075 (-2.49%) 06/03/22 What You Missed On Wall Street This Morning NVS Novartis $89.27 / +0.16 (+0.18%) 01/19/22 Meet Sangamo: Fly exclusive interview with CEO Sandy Macrae, COO Mark McClung 01/18/22 Fly Intel: Pre-market Movers 12/16/21 Fly Intel: Pre-market Movers NEO NeoGenomics $8.11 / +0.04 (+0.50%) 05/06/22 Proven algorithm says sell these stocks now 04/29/22 Proven algorithm says sell these stocks now 04/27/22 Fly Intel: Pre-market Movers 03/29/22 What You Missed On Wall Street On Tuesday EXEL Exelixis $18.95 / -0.105 (-0.55%) 03/14/22 Fly Intel: After-Hours Movers 02/18/22 What You Missed On Wall Street On Friday 02/18/22 What You Missed On Wall Street This Morning CSTL Castle Biosciences $20.66 / +1.535 (+8.03%) 04/04/22 Fly Intel: After-Hours Movers CBIO Catalyst Biosciences $1.34 / +0.11 (+8.94%) 05/09/22 What You Missed On Wall Street This Morning CAH Cardinal Health $53.94 / +0.1 (+0.19%) 05/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/12/22 What You Missed On Wall Street On Tuesday 04/12/22 What You Missed On Wall Street This Morning 04/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BDSX Biodesix $1.45 / -0.005 (-0.34%) 04/12/22 Fly Intel: Pre-market Movers 04/11/22 Fly Intel: After-Hours Movers ARVN Arvinas $45.33 / +1.11 (+2.51%) 05/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ALKS Alkermes $29.06 / -0.225 (-0.77%) 04/20/22 What You Missed On Wall Street On Wednesday 04/20/22 What You Missed On Wall Street This Morning 04/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ADAP Adaptimmune $1.63 / -0.03 (-1.81%) 03/14/22 What You Missed On Wall Street On Monday 03/14/22 What You Missed On Wall Street This Morning ACLX Arcellx $13.44 / +0.815 (+6.46%) 03/26/22 Opening Day: AN2 Therapeutics rises in public debut after upsized IPO 02/05/22 Opening Day: Arcellx raises $124M in Wall Street debut ACET Adicet Bio $11.21 / -0.29 (-2.52%) 05/26/22 Fly Intel: After-Hours Movers 03/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/06/21 Wall Street in Fives - Must Read Lists for Monday 12/06/21 Wall Street in Fives - Must Read Lists at Midday ABBV AbbVie $146.29 / -0.92 (-0.62%) 05/23/22 What You Missed On Wall Street On Monday 05/23/22 What You Missed On Wall Street This Morning 05/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/10/22 What You Missed On Wall Street On Tuesday A Agilent $129.14 / +0.69 (+0.54%) 05/24/22 Fly Intel: After-Hours Movers 03/28/22 Fly Insider: GameStop, Agilent among this week's notable insider trades 06/17/22 Biopharma;Biotech 07/14/22 Biotech/Biopharma 06/07/22 Global Industrials & Transportation Conference 06/08/22 Global Healthcare Conference 09/07/22 2022 Wells Fargo Healthcare Conference 06/06/22 Adicet Bio - ACET 08/06/22 Extended PDUFA Date for MYFEMBREE 06/06/22 Invitae Corporation 06/10/22 Roche 06/14/22 Puma Biotechnology, Inc. 06/15/22 Aura Biosciences , Inc. 06/16/22 Arvinas, Inc. 06/16/22 FibroGen, Inc. 09/19/22 Novartis RTX PFE NVTA NEO CBIO BDSX ABBV A RTX Raytheon Technologies $96.73 / +0.345 (+0.36%) 03/21/22 Raytheon Technologies call volume above normal and directionally bullish 02/23/22 Unusually active option classes on open February 23rd 01/10/22 Raytheon Technologies put volume heavy and directionally bearish 01/04/22 Raytheon Technologies call volume above normal and directionally bullish PFE Pfizer $53.19 / -0.01 (-0.02%) 05/20/22 Early notable gainers among liquid option names on May 20th 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish NVTA Invitae $2.94 / -0.075 (-2.49%) 05/03/22 Invitae options imply 14.1% move in share price post-earnings 02/24/22 Invitae options imply 14.1% move in share price post-earnings NEO NeoGenomics $8.11 / +0.04 (+0.50%) 05/04/22 Largest borrow rate increases among liquid names CBIO Catalyst Biosciences $1.34 / +0.11 (+8.94%) 05/23/22 Unusually active option classes on open May 23rd BDSX Biodesix $1.45 / -0.005 (-0.34%) 04/12/22 Unusually active option classes on open April 12th ABBV AbbVie $146.29 / -0.92 (-0.62%) 04/29/22 Unusually active option classes on open April 29th 02/24/22 AbbVie put volume heavy and directionally bearish 01/24/22 AbbVie put volume heavy and directionally bearish A Agilent $129.14 / +0.69 (+0.54%) 05/24/22 Agilent options imply 4.7% move in share price post-earnings
Hot Stocks	Biodesix announces research agreement with top U.S. cancer center » 06:01 06/03/22 06/03 06:01 06/03/22 06:01 BDSX Biodesix $1.43 / +0.055 (+4.00%) Biodesix announced that… Biodesix announced that it intends to develop a new novel minimal residual disease test as a part of a master sponsored research agreement with Memorial Sloan Kettering Cancer Center. In addition, the MSRA between MSK and Biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer. Biodesix will utilize its array of genomics, proteomics, artificial intelligence, and machine learning capabilities with the aim of developing and commercializing oncology biomarker assays in collaboration with MSK. Initially, the teams will collaborate to develop a highly sensitive molecular MRD test on the new ddPCR platform, the Bio-Rad QX600 ddPCR System. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options BDSX Biodesix $1.43 / +0.055 (+4.00%) 04/11/22 Biodesix director Strobeck buys $1M in company shares 03/29/22 Biodesix announces publication of data from GeneStrat NGS test studies 03/07/22 Biodesix announces stock buyback for up to $50M with Lincoln Park Capital 03/03/22 Biodesix's PIR test shows predictive efficacy in lung cancer BDSX Biodesix $1.43 / +0.055 (+4.00%) 05/12/22 Canaccord Biodesix price target lowered to $7 from $10 at Canaccord 04/20/22 Cowen Biodesix initiated with an Outperform at Cowen 04/18/22 BTIG Biodesix price target lowered to $10 from $17 at BTIG 03/15/22 Canaccord Biodesix price target lowered to $10 from $18 at Canaccord BDSX Biodesix $1.43 / +0.055 (+4.00%) 05/11/22 Biodesix still sees 2022 revenue $37.5M-$39.5M, consensus $38.41M 05/11/22 Biodesix reports Q1 EPS (50c), consensus (40c) 03/14/22 Biodesix sees FY22 revenue $37.5M-$39.5M, consensus $35.5M 03/14/22 Biodesix reports Q4 EPS (49c), consensus (49c) BDSX Biodesix $1.43 / +0.055 (+4.00%) 04/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/12/22 Fly Intel: Pre-market Movers 04/11/22 Fly Intel: After-Hours Movers 06/05/22 2022 ASCO Annual Meeting BDSX Biodesix $1.43 / +0.055 (+4.00%) 04/12/22 Unusually active option classes on open April 12th

Over a month ago
Recommendations	Biodesix price target lowered to $7 from $10 at Canaccord » 07:58 05/12/22 05/12 07:58 05/12/22 07:58 BDSX Biodesix $1.56 / -0.265 (-14.52%) Canaccord analyst Kyle… Canaccord analyst Kyle Mikson lowered the firm's price target on Biodesix to $7 from $10 and keeps a Buy rating on the shares. The analyst said he believes the company's core business is rebounding nicely and Biodesix appears to be gradually executing on its growth strategy. He continues to believe the shares offer significant upside potential from current levels. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options BDSX Biodesix $1.56 / -0.265 (-14.52%) 04/11/22 Biodesix director Strobeck buys $1M in company shares 03/29/22 Biodesix announces publication of data from GeneStrat NGS test studies 03/07/22 Biodesix announces stock buyback for up to $50M with Lincoln Park Capital 03/03/22 Biodesix's PIR test shows predictive efficacy in lung cancer BDSX Biodesix $1.56 / -0.265 (-14.52%) 04/20/22 Cowen Biodesix initiated with an Outperform at Cowen 04/18/22 BTIG Biodesix price target lowered to $10 from $17 at BTIG 03/15/22 Canaccord Biodesix price target lowered to $10 from $18 at Canaccord 02/15/22 Canaccord Biodesix price target lowered to $18 from $22 at Canaccord BDSX Biodesix $1.56 / -0.265 (-14.52%) 05/11/22 Biodesix still sees 2022 revenue $37.5M-$39.5M, consensus $38.41M 05/11/22 Biodesix reports Q1 EPS (50c), consensus (40c) 03/14/22 Biodesix sees FY22 revenue $37.5M-$39.5M, consensus $35.5M 03/14/22 Biodesix reports Q4 EPS (49c), consensus (49c) BDSX Biodesix $1.56 / -0.265 (-14.52%) 04/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/12/22 Fly Intel: Pre-market Movers 04/11/22 Fly Intel: After-Hours Movers 06/05/22 2022 ASCO Annual Meeting 05/24/22 Biodesix, Inc. BDSX Biodesix $1.56 / -0.265 (-14.52%) 04/12/22 Unusually active option classes on open April 12th

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial